Cancer news and blogs 

  • The latest treatment research featured at hepato-pancreactic and biliary cancer education event
    27 June 2019

    Positive results from clinical trials of new immunotherapies and systemic chemotherapies for both hepato-cellular carcinoma (HCC) and hepato-pancreactic and biliary (HPB) cancers were previewed at our HPB education event last month, prior to their presentation at the American Society of Clinical Oncology.

    Professors Tim Meyer and John Bridgwater explained that these developments could lead to significant changes in the treatment and outcomes in these rarer cancers where outcomes are poor and new treatments slow to emerge. 

    Also on the agenda was the often overlooked issue of nutrition and HPB surgery. Mary Phillips, an advanced specialist dietitian at the Royal Surrey County Hospital, shared her experience of setting up a nutritional service for patients having HPB surgery and the positive improvement this has made to their outcomes.  Mary's lecture was a superb field guide to setting up an ERAS protocol. Her presentation is available with the HPB pathway board documents here.

    Satya Bhattacharya, HPB pathway board director, said, “It was wonderful that we were able to organise another informative event with speakers who are experts in their fields. I was particularly pleased that the session was so well attended by clinical nurse specialists, as they have often been overlooked in the past.”

    The North Central and East London Cancer Alliance is grateful to the speakers for giving up their time and to Merck Sharp & Dohme Ltd for their contribution to the cost of running the event.


  • Improving outpatients teams’ support for people
    with cancer
    7 May 2019

    “Thank you for your letter… It means a lot to us both. It also helps us to see that help will follow, however it comes. That’s reassuring to us,” says the relative of a University College Hospital patient.

    Cancer patients and their carers are getting a much better experience of outpatient care and treatment, through the Enhanced Supportive Care (ESC) programme. Like palliative care, ESC addresses physical, psychological and social symptoms of cancer and its treatment. ESC helps patients move into care after treatment, providing enhanced rehabilitation, secondary cancer prevention advice, survivorship coaching and end of life care.

    The programme provides:

    • coordinated and timely access to supportive care
    • lower likelihood of emergency admission to hospital
    • informed choice of treatment at all stages
    • opportunities for patients to be fully involved in treatment decisions
    • optimised use of chemotherapy

    One patient from Barking, Havering and Redbridge University Hospitals NHS Foundation Trust (BHRUT) avoided three possible GP visits due to contact with the ESC team, and avoided hospital admission on at least one occasion because she had access to acute care when experiencing early pain. Following considered discussions with the ESC team, the patient decided not to have chemotherapy, which it was unlikely she would have managed to complete. She spent 20% more time at home in her last 105 days, and avoided end of life admission to hospital. As well as giving the patient a better end of life with those closest to her, ESC saved the system £7,806 and saved the patient £244 in travel expenses.

    ESC began as a pilot scheme at the Christie Hospital in Manchester in 2014. By April 2017 it had been implemented in 23 sites nationally. This included two trusts in our Cancer Alliance: BHRUT and University College London Hospitals NHS Foundation Trust (UCLH) where ESC has been implemented to help appropriate patients with breast, ovarian, lung, and upper gastrointestinal (GI) cancers. Treatment centres have experienced a reduction in cost and demand placed upon capacity, due to fewer unplanned admissions and financial savings mainly due to a reduction in untimely and inappropriate end of life treatments.

    “This programme has sought to foster a more positive understanding of supportive care - it’s not just about end of life care,” says Dr Jane Neerkin, a consultant in palliative medicine at UCLH and the Clinical Lead for this project. “Supportive care fills a gap in helping the increasing numbers of patients who are now ‘living with cancer’ and who need the support of teams that have expertise in managing the range of issues that cancer and its treatment can cause in patients.”

    Do you want to find out more about this programme, or are you interested in adopting it in your area? Please contact the team:

  • Don't forget non-smokers say lung cancer experts
    26 April 2019

    The Journal of the Royal Society of Medicine has published a research paper on lung cancer in people who have never smoked. It argues that because the vast majority of work in public health and individual patient care is centred on smoking as a major cause, the estimated 6,000 deaths a year from lung cancer in non-smokers has been ignored. Some of key factors here are second-hand smoke, exposure to carcinogens in the workplace and air pollution. 

    Professor Mick Peake, clinical director of the Centre for Cancer Outcomes here at the UCLH Cancer Collaborative, is a co-author of the paper. He says: “Despite advances in our understanding, most people who have never smoked do not believe they are at risk and often experience long delays in diagnosis, reducing their chances of receiving curative treatment.”

    “Drawing attention to the contribution of underlying risk factors to lung cancer in never-smokers presents opportunities to reinforce efforts to tackle other major public health challenges. For example, the impact of passive smoking and air pollution on lung cancers adds weight to the government’s ambitions to improve air quality and the public, clinicians and policy makers must all be aware of this relationship.”

    The paper’s authors admit that lung cancer in non-smokers is a diagnostic challenge, particularly for GPs who are seeking to balance over-investigation with early diagnosis and high-quality care. People who have never smoked, but who may unknowingly have lung cancer, are half as likely as smokers to visit their GP with typical symptoms such as cough, breathing difficulties or coughing up blood.

    However, as the disease is more common in never-smokers than most people think, increasing awareness could help lead to earlier diagnosis, reduce the blame culture around lung cancer and re-balance research funding to understand the disease better in both smokers and non-smokers.

    The SUMMIT study on lung cancer is a major programme of the UCLH Cancer Collaborative. It has just got underway and will be firstly screening smokers and then non-smokers to identify and treat early signs of lung cancer, and to work towards the development of a diagnostic blood test. Read more about SUMMIT here.

  • Skilling up in ultrasound for ovarian cancer diagnosis
    8 April 2019

    Improved skills for reporting of ultrasound scans for possible ovarian cancer are important for reducing women’s anxiety and for making urgent referrals if necessary.                

    Over 150 sonographers and radiologists from across the Cancer Collaborative region have completed training in the IOTA (International Ovarian Tumour Analysis) Simple Rules over the last year.  This process empowers them to confidently and accurately differentiate between benign ovarian cystic lesions and malignant masses without the need for a CT scan.

    For GPs receiving the ultrasound reports it also means they have access to better information before making a decision to refer a patient to the urgent cancer pathway. Women’s minds can be put at ease if cancer can be ruled out but if a malignant mass is suspected then an urgent referral can be made by a GP with confidence.

    The training sessions were run by London Cancer and the north and east London Gynaecology Pathway board, led by consultant Alex Lawrence, and doctors Suzanne Johnson and Anju Sahdev.

    Course participants have said they feel more confident about using the IOTA Simple Rules on a day-to-day basis. Back in their hospitals sonographers and radiologists will be supported by ‘IOTA ‘champions’ who will facilitate their ongoing learning and improvement.

  • Women respond to recruitment drive for ovarian cancer surveillance programme
    1 April 2019

    Over 800 women have already joined the ALDO (Avoiding Late Diagnosis of Ovarian Cancer) project, just six months since its launch. The ALDO project, led by the UCLH Cancer Collaborative, is screening women who carry mutations in BRCA1 or BRCA2 genes, which puts them at high risk of developing ovarian cancer. It is hoped that the ALDO project may lead to a national NHS surveillance programme for such women.

    The project began recruiting participants in August 2018. In just over six months, 800 women have joined from 13 participating NHS Clinical Genetics and Familial Gynaecological Cancer clinics across England and Wales. Surveillance will last for one year, but the project is now planning to seek funding to extend this into a second year.

    The only way to prevent ovarian cancer is to remove the ovaries and fallopian tubes as a precautionary measure. For many women this is a significant and life-changing choice to make. Women may delay a decision on this surgery for a number of reasons, such as wanting to have children, avoiding early menopause and its associated problems, or because they have other health problems which make surgery too risky.

    Dr Adam Rosenthal, Consultant Gynaecologist at UCLH and medical director of the ALDO project said: “It’s great to see so many women at high risk of ovarian cancer join the project. They desperately need options other than surgery to remove their fallopian tubes and ovaries. While surgery is the right thing for them to do from a safety perspective, it has significant down-sides, so it can take them many months or even years to make up their mind to go ahead with it. These women know surveillance can’t prevent cancer, but it may improve their experience and their outlook if they are diagnosed before they’ve had preventive surgery.”

    Each woman in the project will have a four-monthly blood test (the ROCA Test) which is specifically designed to detect the likelihood of having ovarian cancer. To date, over 600 women have received their first ROCA test and from that, a small group of women (less than 4%) have been advised to have a transvaginal ultrasound examination.

    At present in the UK there is no standard ovarian cancer surveillance recommended or in place for this group of high risk women who delay risk-reducing surgery. The ALDO project aims to evaluate ROCA Test surveillance in a ‘real world’ setting, to gather sufficient evidence to help the NHS evaluate the health and economic impact of adopting it as standard practice.

    At the end of the project the evaluation will be shared with the National Institute for Health and Care Excellence (NICE) and NHS clinical commissioners so the benefits for patients can be assessed.

    Visit The ALDO Project for more information.

  • Cervical screening saves lives says new campaign
    5 March 2019

    A new campaign has launched to raise awareness of the risks of cervical cancer and highlight the benefits of screening, reminding women that cervical screening can stop cancer before it starts. The Public Health England campaign, which launched on 5 March, encourages all women to respond to their cervical screening invitation letters, and if they missed previous invites, to book an appointment at their GP practice.

    Two women die every day from cervical cancer in England. Women can protect themselves against the risk of cervical cancer by attending their screening when invited; it is estimated that cervical screening saves around 5,000 lives each year. However, cervical screening is at a 20-year low, with one in four women in the UK not attending their test.

    Says Alexandra Lawrence, clinical director of the gynaecology pathway board for north and east London: “I encourage every woman in north and east London to have a smear as soon as they receive their invitation or if they have missed a smear to book in with their GP. This can save your life.”

    Everyone with a cervix, which is most women and many trans people, between the ages of 25 and 64 are invited to attend cervical screening every three or five years depending on their age.

    The screening test, which only lasts a few minutes, is not a test for cancer. In fact, attending regular screening can help stop cervical cancer before it starts by preventing potentially harmful cells from developing.

    The ‘Cervical Screening Saves Lives’ campaign empowers women with the knowledge and tools to get screened. Advice on making the screening test more comfortable includes:

    • Talk to your nurse - they are trained and experienced in how to make your test comfortable.
    • Wear a loose skirt or dress, you may feel more covered during your appointment.
    • Take a friend or family member with you if it will help you feel more comfortable.

     For more information, visit

  • GP practices trained in electronic systems to provide better cancer care

    Forty-one GP practices across north central and east London now have their teams trained to implement and effectively use our Electronic Safety Netting Toolkit (e-SN) which is nationally available on EMIS Web. Safety netting ensures that patients who are referred to a hospital for investigations or who have symptoms which may indicate serious disease are followed up in a timely and appropriate manner. This EMIS tool allows this process to be tracked electronically.

    Five incentivised workshops were held between November 2018 and January 2019 as part of a commissioned package of training using 2018/19 Cancer Transformation funding. The content included clinical updates from a variety of Cancer Collaborative projects.

    Locating the workshops in both central and easterly locations increased accessibility for all practices. There was good attendance all round, with the best turn out from Barnet, Redbridge, Tower Hamlets and Islington Clinical Commissioning Groups.

    Feedback from the events revealed:

    •    98 % had increased appreciation of safety netting systems
    •    97 % thought the tool offered a better way of safety netting than their current systems
    •    87 % felt confident enough with the tool to teach others in their practice to use it
    •    98 % saw the versatility of the tool to be used in safety netting outside cancer
    •    96 % of attendees were happy or very happy with the workshops overall

    Attendees’ comments have informed changes to the toolkit which are now being actioned by EMIS Web. The template will no longer be named as a ‘pilot’ and the search function has been refined. There will be further updates over the next few months.

    A CRUK Early Diagnosis Advisory Group grant has been awarded to evaluate the tool.  This formal research evaluation will be undertaken by a collaboration of researchers from UCL and University of Oxford.  It will enrich our understanding and practice of safety netting.

    More E-SN workshops will follow for networks of practices on sites local to CCGs. Our plan is to train local trainers to deliver these new sessions.

    If you would like E-SN training please contact Vanessa Ponnusamy at

  • Knowledge sharing at the London Cancer gynaecology education event
    4 February 2019

    Clinicians and patient representatives from across north central and east London, and west Essex came together to learn about developments in care for patients with gynaecological cancers at an event organised by the London Cancer Gynaecology Pathway Board on 21 January.

    Alex Lawrence, Pathway Director and Consultant Gynaecological Oncologist, welcomed more than 45 gynaecologists, clinical nurse specialists, sonographers, GPs and patients to the meeting where they heard presentations on a number of interesting topics, including:

    • Life after cancer - can we use HRT and how can we protect bones?
    • Psychosexual issues in gynaecological cancers
    • Enhanced supportive care in ovarian cancer
    • Updates in radiotherapy and bowel toxicity

    Feedback was overwhelmingly positive.  Attendees found the day valuable for disseminating new knowledge and enabling networking between professional groups. The afternoon was described by attendees as an “excellent learning event” and “a fantastic local resource…”

    “The event was a great success, bringing together colleagues and patient representatives. The presenters shared expertise in their specific fields, which will help us all to improve care for gynaecological cancer patients in our area”, said Alex Lawrence. “We had many suggestions for further topics and I look forward hosting similar events in the future.”


    Presentations from the event are available here.

  • New Joint Chief Medical Officers for the UCLH Cancer Collaborative
    28 January 2019

    As we settle into 2019, the UCLH Cancer Collaborative rings the changes.

    Dr Afsana Bhuiya, an Islington GP, and Professor Muntzer Mughal, Consultant Oesophogogastric Surgeon and Honorary Clinical Professor in Surgery at UCL, have been appointed interim joint Chief Medical Officers (CMO) for the UCLH Cancer Collaborative.

    This follows Professor Kathy Pritchard-Jones standing down from the CMO role at the end of 2018, after eight years at the helm.  

    The new joint CMOs will be known to many through their current roles in the Collaborative.  Professor Mughal leads on MDT improvement in the Cancer Academy and Dr Bhuiya is the GP improvement lead in the Macmillan Integrated Cancer (MICa) programme. These interim appointments have been made pending a governance review of the Cancer Collaborative by Professor Sir Mike Richards.

    “I am delighted we have made such excellent appointments to cover during this period of change,” says Prof Geoff Bellingan, medical director for cancer and surgery at UCLH and professor of intensive care medicine at UCL. “These are people who will be able to take the cancer agenda for NCEL forward and who will also implement the outcomes from the governance review.”

    A joint appointment of this kind enables the Cancer Collaborative to draw on Professor Mughal’s and Dr Bhuiya’s combined expertise and experience, particularly  to strengthen our work with primary and community care, and our engagement with the wider STP agendas in both North Central London and North East London.

    Dr Bhuiya says: “I am honoured and excited to be part of the leadership for the Cancer Collaborative, which I have been part of as it has grown over the years. The challenges ahead are clear and further consolidated by the NHS Long Term Plan. I am keen to harness our influence in the emerging community structures to make the most impact on our patients, by involving primary care and supporting projects such as the roll out of FIT (a new test to help diagnose cancer).

    Professor Mughal says: “I am delighted to take up this role and look forward to working with our partners in refreshing the Cancer Collaborative’s work to align with the recently published NHS Long Term Plan. My immediate task is to develop and support effective MDT working, as well as ensuring that best practice tumour pathways are applied consistently across our alliance to achieve best outcomes for patients and meet national cancer performance targets.”

    Professor Pritchard-Jones worked alongside former Cancer Collaborative Chair, Pelham Allen. They led the organisation from its inception as the new integrated cancer system for north central and east London and west Essex, through its period as an NHS England Cancer Vanguard, to its position now as the cancer alliance for north central and east London.

    She will continue to be involved in the work of the UCLH Cancer Collaborative, as she takes over the role of Chair on an interim basis following Pelham Allen’s retirement in November 2018.  Her work as an MDT improvement coach with the Cancer Academy goes on and she joins the Centre for Cancer Outcomes to lead on outcomes measurement in children and young people’s cancers.

    Says Professor Pritchard-Jones: “It has been a tremendous privilege to lead the creation of an integrated cancer system across all providers in north central and east London and west Essex over the last eight years. Through a shared ambition to improve patient outcomes and experience, we’ve developed and introduced new ways of working together. I am grateful to all the patients, hospital clinicians and managers, GPs, commissioners and public health colleagues for their unswerving support. I also thank Pelham Allen for his wise advice and steady hand at the tiller, always keeping the focus on the patient. My ambition is to ensure I carry this ethos forward as chair, confident that our stakeholders will go on supporting the new joint CMOs and that we will make good progress in 2019.”


    For further information please contact


    Afsana Bhuiya, interim CMO

    Muntzer Mughal, interim CMO

  • Lung patient navigators and MDT coordinators come together at pathway improvement event
    10 January 2019

    The London Cancer lung pathway board held an event for the new Patient Navigators and MDT Coordinators on 10 January which focused on their role in delivering the National Optimal Lung Cancer Pathway (NOLCP). Patient navigators will arrange diagnostic tests, act as a first point of contact for patients’ administrative queries and collect data to demonstrate the achievement of the new pathway.

    Pathway Director, Dr Neal Navani, welcomed 10 representatives from across north and east London and explained the importance of the NOLCP and patient navigators.  Dr William Ricketts, Consultant Respiratory Physician, shared the Barts Health experience and Sam Purse from the North Middlesex, our longest standing navigator, provided her ‘on the ground’ perspective. The afternoon was designed to give opportunities for delegates to discuss the pathway and for networking with their counterparts.

    The pathway is aiming for diagnostic and outpatient appointments as quickly as possible and in parallel, so that a patient’s treatment is underway by day 49 of the national 62 days waiting time standard. Creating a smooth process for patients is central in these developments.

    “The event feedback was uniformly positive with everyone committed to collaborating towards delivering the national pathway for our patients. Patient navigators are new roles, paid for through the cancer transformation fund, so it is encouraging to see how they are developing,” says Neal Navani. “Comments included, ‘It was very insightful to learn the impact of our work’ and ’it is very valuable to share information and knowledge’.”

    The lung pathway board will be working with our navigators to build on this spirit of collaboration in the coming months and there will be a follow up event in the summer.

    The evaluation report can be found here. If you have any queries please get in touch with Simon Evans at

  • Millimetres matter
    10 January 2019

    At the end of November, the UK Lung Cancer Coalition (UKLCC), a collaboration involving the UK’s leading lung cancer experts, senior NHS professionals, charities and healthcare companies, held a national workshop on earlier diagnosis of lung cancer. The workshop coincided with the launch of the UKLCC’s Millimetres Matter report. The report calls for, and offers assistance towards, implementing the National Optimal Lung Cancer Pathway (NOLCP).

    According to the report, just a quarter (27%) of lung cancer patients in England receive an early diagnosis (stage I or II), and only around three quarters (72.6%) of lung cancer patients get treated within the current 62-day national cancer waiting time standard. The NOLCP aims to offer faster access to diagnostic tests and treatment (by day 49 rather than by day 62).

    Dr Neal Navani, London Cancer Lung Pathway Board Director and Consultant in Thoracic Medicine at UCLH, made the case for the NOLCP at the workshop. Dr Navani commented:

    “The rationale for the NOLCP is clear. In just a few weeks, a lung tumour can grow. This can then affect treatment options and chances of long term survival. The workshop and report substantiate our efforts to build on the progress we have already made to implement the pathway fully in our Trusts.”

    For further information on the work of the London Cancer Lung Pathway Board and its commitment to implement the NOLCP, please contact Simon Evans, Pathway Manager, at

  • UCLHCC at the Britain Against Cancer conference
    13 December 2018

    Tuesday 4 December 2018 saw the return of the annual Britain Against Cancer conference to Central Hall in Westminster.

    The event provides a forum for patients, NHS organisations, local authorities, charities, research bodies, policymakers, and government ministers to come together to discuss the progress of the implementation of the national Cancer Strategy, to identify issues and opportunities, and to debate priorities for cancer care in 2019. The conference seeks to ensure that these reflect the things that matter to patients, their families, and carers. This year’s event was particularly noteworthy in that it celebrated 20 years of the All Party Parliamentary Group on Cancer (APPGC).

    The UCLH Cancer Collaborative was delighted to host a stand at the conference alongside colleagues from the other two London cancer alliances: RM Partners, and South East London Cancer Alliance. As the cancer alliance for north central and east London and west Essex, our work focuses on supporting the development of integrated pathways of care for people in our geographical area who are living with and beyond cancer. The conference provided a valuable opportunity for us to showcase the three alliances’ work together across London: highlighting the ways in which our programmes complement and reinforce one another to support the delivery of high quality cancer care to our respective populations.

    Our stand was busy throughout the event, and we were thrilled to receive interest from patients and NHS colleagues, as well as from Steve Brine MP, Parliamentary Under Secretary of State for Public Health and Primary Care, and Lynda Thomas, CEO of Macmillan Cancer Support.

    At the close of the afternoon speaker session, Cally Palmer, NHS England’s National Cancer Director, highlighted the fact that cancer survival is currently at its highest level, with data gathered in 2015 indicating that 8,500 more people survived their cancer for at least one year than was the case four years earlier. Her presentation celebrated the many recent achievements of the UK cancer community:

    • Establishment of 10 multi-disciplinary diagnostic clinics (MDCs)—one of which is based here at UCLH
    • Availability of six new molecular diagnostic tests funded by the NHS
    • Delivery of the largest radiotherapy investment and modernisation programme for fifteen years
    • Patients rating their cancer care as ‘8.8 out of 10’—the best results ever
  • London Cancer update - biliary disease event
    30 November 2018

    Although considered a rare cancer, cholangiocarcinoma (cancer of the bile duct) is the world’s second most common liver cancer.  Late diagnosis of cholangiocarcinoma often contributes to poor rates of survival for this type of cancer.
    In November, the London Cancer the Hepato-Pancreatic Biliary (HPB) Pathway Board held a biliary cancer educational event, hosted by the pathway director Mr Satya Bhattacharya. The event updated clinicians from across the network in the latest methods for diagnosing and treating biliary cancer, and provided information from trials that have implications for this cancer.
    The speakers were able to provide a variety of perspectives. Mr Deepak Hariharan, Prof Brian Davidson and Dr George Webster represented trusts from across the network.  Due to the skill and knowledge mix of the speakers, both surgical and oncological aspects of treatments were discussed.
    At the end of each presentation, a series of case studies were presented, which gave the opportunity for interaction and debate on the best course of treatment.
    Mr Bhattacharya said “It’s wonderful that we have been able to hold an educational event dedicated to one of the rarer cancers and that this event provided an opportunity for discussion amongst healthcare professionals. We hope to hold more such events in the future”.
    London Cancer would like to thank all of the speakers for giving up their time. A special thank you is given to Mr Hariharan, who stepped in on the day to cover a colleague who was unexpectedly unavailable.
    Presentations from the event can be found under the additional Pathway Board Documents section of the website:

  • Launch of the SUMMIT study
    Tuesday 4 December 2018

    Today sees the launch of the largest ever UK lung cancer screening study which will seek to detect lung cancer early amongst at-risk Londoners. Read all about it here


  • Bladder Cancer Support group marks its second birthday
    28 November 2018

    The UCLH bladder cancer support group – a collaboration between the urology oncology clinical nurse specialists and the support and information team – recently marked its two year anniversary.

    This support group is for anyone affected by bladder cancer.  Each month, there’s an education session and every other month, an open support session facilitated by Vikki Riley, clinical nurse specialist in the Macmillan Support and Information Service.  The group provides an opportunity for patients to meet up with other people.  A core group of 12 meets regularly but over 30 patients have dropped in over the past couple of years

    The group provides space at a time that can be very distressing as one patient described “It provides a safe space to discuss, share and listen to each others’ experiences of bladder cancer”.

    Vikki added, “The treatment is invasive and challenging. One man who needed to make a decision about radical surgery felt that he was able to face his major surgery by spending time with an inspirational woman who had been through what he was facing. He, in turn, has offered that to others. The group provides a safe place for people to talk and share experiences together with kindness, humour and compassion'.

    Invitation to the group has been opened up to all patients affected by bladder cancer in hospitals covered by London Cancer (north and east London and west Essex).It is held on the third Thursday of every month, from 12 -1.30pm , except December in The Macmillan Support and Information Centre, at the University College Hospital Macmillan Cancer Centre, Huntley Street, WC1E 6AG​ 

  • Supporting people with brain and spine cancer
    8 November 2018

    Last month, the first London Cancer brain and spine patient engagement event took place, hosted by neurosurgeon and pathway director, Mr Edward McIntosh. Forty-five people - including patients and their families and carers, charity workers, and clinical staff - came together to hear about important current issues relating to brain and spine cancer. The agenda was developed by Mr McIntosh with input from our patient representative, ensuring the content of the event was relevant to patients attending. Speakers and subjects included:

    • Dr Wai Liu, a Senior Research Fellow at St George's University of London, on cancer and cannabinoids
    • Dr Paul Mulholland, Medical oncologist at the National Hospital for Neurology and Neurosurgery, on current research in the area
    • Dr Matthew Williams, Medical Oncologist at Imperial, on the ketogenic diet.

    The audience was given the opportunity to put questions to speakers and chat informally during the breaks.

    The event is the start of longer-term plan to engage patients in the work of the pathway board, Mr McIntosh said, “The London Cancer Brain and Spine Pathway Board hopes that the event acts as a spark for greater patient involvement in in our work programme. The patients and carers I spoke with during the evening seemed to value the event, and many people said to me that they are keen to stay engaged with our work, which is really encouraging. It was a team effort and I would particularly like to thank our fantastic speakers, who gave extremely interesting and relevant talks, as well as the Brain Tumour Charity, Brains Trust, Brain Tumour Research, the National Brain Appeal and the Macmillan Centre for Cancer Outcomes for giving up their time to make the event such a success”.

    London Cancer is the integrated cancer system serving north east and central London and west Essex. The system works with healthcare providers to deliver comprehensive and seamless cancer care to all patients from diagnosis, through treatment, to living with and beyond cancer. The brain and spine tumour pathway board is one of 22 boards, which focus on a range of specific cancer types.

  • Get involved with cancer - short film about our Patient and Carer Network
    23 October 2018

    UCLH Cancer Collaborative is delighted to launch a new three minute film encouraging people affected by cancer to join the Patient and Carer Network.


    It features Carol and Andrew, two members of the Network, talking about how their involvement has made a difference since joining.

    Please feel free to share with any people affected by cancer who may be interested in getting involved. Visit our Get Involved with Cancer webpage for more information.

  • Evaluating the Cancer Vanguard
    22 October 2018

    Until March 2018, UCLH Cancer Collaborative were part of the former national Cancer Vanguard – a partnership between UCLH Cancer Collaborative, Greater Manchester Cancer Vanguard Innovation and RM Partners. The Cancer Vanguard was established to pilot and roll out new models of care that would provide innovative high quality cancer care across the whole patient pathway.

    Over the last 18 months, the Cancer Vanguard has been working with external evaluators from Technopolis Group and Optimity Advisors to determine the impact of its work on cancer outcomes and patient experience; the value delivered across all three Vanguard partners; and whether the work can be replicated.

    For more information about the evaluation, and to download the evaluation report and executive summary, go to the Cancer Vanguard website.

  • Making cancer care safer
    17 October 2018

    Liz Simcock and Selena Hoskins – both specialist nurses at UCLH – presented at the World Congress of Vascular Access in Copenhagen recently. They have done some work that has halved thrombosis rates in sarcoma patients undergoing chemotherapy - proving that a small change can make a big difference to patient care.
    Liz explained, “Some patients having cancer treatments need a long-term intravenous line fitted called a PICC. At UCLH we fit 1200 PICCs each year. Although a tried and tested approach, there are risks of complications occurring. One of the possible complications of having a PICC is that it can cause a deep vein thrombosis (DVT) in the arm (where the blood clots in the vein). This can be easily treated but involves daily injections to thin the blood and sometimes the PICC has to be removed. We are doing our best to reduce the number of PICC patients who get develop a DVT, and a few years ago, noticed that patients with sarcomas – were more likely to develop a DVT (13% of sarcoma patients were getting DVTs). We started using a different kind of PICC for these patients which has reduced the incidence of DVT in that group of patients from 13% to 6%. It was great to be able to share our learning with colleagues at the international conference”.
  • London Cancer Urology Annual Review event
    8 October 2018

    London Cancer held its 2018 Urology Annual Review event at the end of September with over 70 delegates from seven trusts across north and east London. A broad range of professions were represented, including clinical specialists, cancer managers, MDT coordinators, data managers and research associates.

    11 speakers presented on the five urological tumour sites - bladder, prostate, penile, testicular and renal. The afternoon provided insight and updates on innovative developments across these tumour sites.  Speakers focused on improvements within operations and technology as well as treatment.  Professor Muntzer Mughal provided an update on the UCLH Cancer Collaborative MDT Improvement program whilst several speakers, most notably Professor John Kelly, highlighted the use of robotics in bladder surgery.

    The event also provided an opportunity to present and evaluate the extent to which innovation has impacted patient care.  Mr Asif Muneer presented the developments within penile cancer surgery, highlighting the importance of balancing quality of life and treatment outcomes.

    Changes in treatments were also considered from a more quantitative and long term view point. Dr Pandora Rudd presented an audit of over 2,000 patients showing how treatment choices have developed over the last seven years in prostate cancer. Each presentation was followed by an interactive Q&A session, which provided attendees with an opportunity to further explore and challenge new areas of development.

    Feedback from the day was positive across the board.  Presentations from every tumour site were nominated by guests as the “most useful topic”.

    Veronica Brinton, a patient representative described the event as “an excellent informal gathering, in size and composition of guests, with really interesting presentations in a very good format”.

    We would like to thank all of our speakers for giving up their time to present. Particular thanks goes to Mr John Hines, who not only presented and also chaired the event, and was invaluable in coordinating behind the scenes. Finally, we would like to thank all our guests, who asked such thought provoking questions and made the day worthwhile.

  • Helping young people move on after cancer
    4 October 2018

    UCLH specialises in treating young people with cancer – but what happens when treatment ends?  Our staff are always looking to improve our patients’ cancer journey – at whatever stage.  With this in mind, Trekstock, an organisation providing young adults with information and support programmes to help them deal with the emotional and physical impact of cancer during and after treatment were recently invited to UCLH for a lunch and learn session.

    The meeting was really beneficial,  as Dr Louise Soanes, Teenage Cancer Trust Nurse Consultant explains, “Twenty nurses, allied health and social care professionals joined us to learn what Trekstock offers young adults - online support and  advice, health and well-being events, Renew - a bespoke physical rehabilitation programme and peer support events and meet ups.   We also heard directly from young adults about how Trekstock has helped them.  Importantly, we discussed how and social care professionals working at UCLH can refer young adults with cancer to Trekstock so that they can make best use of the services on offer and move on after cancer”.
    Find out more about Trekstock here:
    Find out more about our cancer services for young adults here.

  • Cancer patient experience survey shows positive results across north and east London and west Essex
    2 October 2018

    Each year, patients being treated for cancer are asked to give feedback on their care through the National Cancer Patient Experience Survey. The local results for 2017 were recently published and help to provide a valuable insight into how people experience cancer services provided.

    UCLH Cancer Collaborative is the Cancer Alliance for north and east London and includes eight hospital trusts whose results were reported in the survey. We were pleased that patients treated at these hospital trusts continued to report that they receive good to excellent care. Overall when asked to rate their care on a scale of zero (very poor) to 10 (very good), respondents gave an average rating of 8.56 in 2017, compared to 8.51 in 2016. Our region also saw an increase in the number of patients reporting that they were offered an opportunity to take part in cancer research – a two percentage point increase between 2016 and 2017.

    The survey also highlighted areas where improvements need to be made. One area needing improvement is professionals in hospitals and primary care working well together across organisational boundaries to give the best possible care to patients. We have made progress but more can still be done.This will be a focus of our work with our partners in hospital trusts and primary care over the coming year.

    UCLH Cancer Collaborative will continue to put people affected by cancer at the heart of our work across the region. Below are just some of the ways in which we are currently are doing this:

    • Actively involving people affected by cancer in the planning, design and strategic oversight of all of our work programmes
    • Supporting people living with and beyond cancer, for example by providing tailored care to help people to live healthily during and after treatment
    • Speeding up diagnosis through multidisciplinary diagnostic centres for patients with vague, but concerning, symptoms that could be cancer
    • Developing a new early diagnosis centre in north east London for patients with conditions that increase their risk of cancer, as well as for monitoring patients with early stage cancer who do not need treatment right away
    • Bringing care closer to home for patients receiving chemotherapy and other cancer treatments through innovative projects with our partners and the pharmaceutical industry
    • Piloting a simple, inexpensive new test to rule-out colorectal cancer, and focusing on the earlier diagnosis of lung cancer through a large-scale lung health check and screening programme
    • Developing the Cancer Academy, an innovative approach to education and training  for staff working in cancer services and for people affected by cancer
      Working with primary care professionals to develop new tools and training for GPs to help them diagnose cancer faster.

    Commenting on the survey, Carol Fenton, member of the UCLH Cancer Collaborative Patient Experience and User Involvement Steering Group, said:  
    “This survey demonstrates the vital importance of patient experience alongside clinical outcomes. People affected by cancer have first hand experience of cancer care in the hospital and community. Therefore, it is hugely important that  people living with cancer are involved in the design and delivery of cancer services in our region and across the country.

    “I joined the patient experience and user involvement steering group to work together with other people affected by cancer, alongside carers, clinicians and other health professionals to drive through improvements across north and east London. I hope that with an ever increasing number and diversity of people living with cancer involved, all voices can be heard, key issues highlighted, new ways of working explored and improvements delivered at pace during the coming year.”

  • New blood cancer guidelines for London published
    27 September 2018

    The three Cancer Alliances in London (UCLH Cancer Collaborative, RM Partners and South East London Accountable Cancer Network) have jointly published new guidelines for the treatment of blood cancers in London. The guidelines cover a range of blood cancers including leukaemia, lymphoma, plasma cell disorders and more.

    This is the first time that blood cancer (also known as haematological cancer) guidelines have been published to cover the whole of London and will help to make sure that all blood cancer patients in London receive the same world class care - from diagnosis to treatment.

    Each London hospital has made a commitment both to implement the new guidelines and review them on an annual basis so they remain at the cutting edge of haematology.

    Prof Ronjon Chakraverty, Professor of Haematology and Director of the London Cancer haematology board, said:

    “Every 14 minutes someone in the UK is diagnosed with a blood cancer and together these cancers represent the fifth largest cancer group. Patients with blood cancer can experience variation in their diagnosis and treatment, in part due to the diverse nature of the conditions. This is why clinicians across London came together to publish the blood cancer guidelines to make sure that all patients receive the same high standard of care wherever they are treated in the capital.  

    “This blood cancer collaboration across London is the first of its kind, and we hope that it will not only influence the treatment of these cancers in London but also across the NHS. We are committed to using the guidelines and hope that our joint work serves as an inspiration to other cancer types and the wider NHS.”

    The guidelines are available on the London Cancer haematology pathway board webpage in the documents section.

  • Gynaecological cancer training for ultrasonographers
    17 September 2018

    The London Cancer Gynaecological Pathway Board held an education morning for over 40 ultrasonographers at Royal London Hospital (Barts Health), a part of the UCLH Cancer Collaborative.

    Chaired by Alex Lawrence, Consultant Gynaecological Oncologist and London Cancer Gynaecology Pathway Director, the day included training on standardising the terminology of adnexal ultrasound scans in order to rapidly determine malignant and benign adnexal masses.

    Speakers included gynaecologists and radiologists from London and Southampton. The following topics were covered at the event;

    • IOTA (International Ovarian Tumour Analysis) terms and definitions
    • Pattern recognition
    • Reporting template.

    Feedback from the day was very positive with lots of attendees highlighting their increase in confidence following the session and confirming that it will change their future practice.

    Alex Lawrence said: “I was very happy with the attendance we received at the training day. This is a successful start to standardising terminology, which will go on to benefit patients and clinicians by reducing the need for MRI scans to classify adnexal masses. I anticipate it will decrease the time to diagnosis for women with ovarian cancer and reduce the numbers of women with benign masses who are unnecessarily referred on the two week wait pathway. ”

    For copies of the presentations, please click here.


  • Two new pathway directors for London Cancer
    4 September 2018

    We are delighted to announce the appointment of two new London Cancer pathway directors.

    Mr Yogesh Bhatt [pictured left], consultant ENT head-neck surgeon at the Royal Free London NHS Foundation Trust, has been appointed to the role of Pathway Director for head and neck cancer.

    Dr Neal Navani [pictured right], consultant in respiratory medicine at University College London Hospitals NHS Foundation Trust, has been appointed Pathway Director for lung cancer.

    You can read more about Yogesh Bhatt, Neal Navani and the other London Cancer pathway directors on our London Cancer webpages

    Prof Kathy Pritchard-Jones, chief medical officer for UCLH Cancer Collaborative, said

    “I am delighted that Yogesh Bhatt and Neal Navani have joined the London Cancer clinical leadership team as Pathway Directors for Head and Neck and Lung cancer, respectively. They both bring a wealth of experience and expertise in the diagnosis and treatment of people with head and neck and lung cancers. I know that they will each make an important contribution to both the care of patients and clinical leadership for the population we serve across in north and east London, west Essex and further afield.”

  • Ovarian cancer pilot NHS surveillance service for women with faulty BRCA gene
    1 September 2018

    UCLH Cancer Collaborative has launched a pilot NHS surveillance service for women who carry a faulty BRCA gene that greatly increases their odds of ovarian cancer.

    The pilot, known as the ALDO project (Avoiding Late Diagnosis in Ovarian Cancer), was featured recently on Channel 5 and ITV London News. It was also featured in the Telegraph, Daily Mail, Technology Networks and Harpers Bazaar.

    Watch the Channel 5 News coverage here.


    The ALDO project aims to recruit 2,000 women aged over 35 from across England and will use Abcodia’s ROCA© Test as part of an NHS service to detect ovarian cancer amongst BRCA-carriers before they have any symptoms. The ROCA Test uses an algorithm to assess changes in the level of the blood chemical CA125, which typically rises in ovarian cancer. Participants will have the ROCA Test every four months.

    This is the first time that this technology has been piloted as an NHS service and heralds a significant step towards meeting recommendations in the National Cancer Strategy to improve early diagnosis. The aim is to confirm the feasibility and cost-effectiveness of introducing ovarian cancer surveillance for women with a faulty BRCA gene across the NHS as standard practice.

    The ALDO project was conceived in 2017 as part of the national Cancer Vanguard’s challenge to industry, aiming to identify opportunities for NHS and industry collaboration that could help to improve the early diagnosis of cancer.

    Mr Adam Rosenthal, consultant gynaecologist at UCLH and clinical director for the ALDO project, who is supported by the NIHR University College London Hospitals Biomedical Research Centre, said: “It is clear that for women with a faulty BRCA gene, having surgery to remove their ovaries and fallopian tubes is the most effective way of preventing ovarian cancer.

    “However, thousands of women choose to delay surgery for a variety of reasons including completing their family or avoiding early menopause. There is currently no national ovarian cancer surveillance for these women.

    “This pilot project will be the first time that an ovarian cancer surveillance service is piloted in the NHS and the hope is that this will become standard practice for women with a faulty BRCA gene in the not too distant future.”

    For further information visit

  • Text reminders to improve cervical screening uptake in London
    15 August 2018

    From September 2018, every GP practice in London will be invited to participate in a new cervical screening text reminder service.

    This initiative will see text reminders sent to all consenting women invited for cervical screening to remind them to contact their GP to book an appointment. The text service is funded by NHS England and supported by UCLH Cancer Collaborative and the other Cancer Alliances in London (RM Partners and South East London Cancer Alliance).

    Evidence shows that a GP endorsed text reminder can improve cancer screening attendance by four per cent and could result in an additional 25,000 women attending their cervical screening appointment.

    Coverage for the cervical cancer screening programme in London is the lowest in England and has declined by 4.6% since 2014, falling from 70.3% in 2014 to 65.7% in 2017.

    This project provides an opportunity to tackle these low rates with minimal input required from busy general practice staff.  The initiative will be rolled-out over the coming weeks and GP practices will be invited to sign up to take part.

    Prof Kathy Pritchard-Jones, chief medical officer for UCLH Cancer Collaborative, said: “The cervical screening text reminder service is an exciting initiative for Londoners that we are delighted to support. It has the potential to greatly improve the number of women attending for their smear test and improve early diagnosis for cervical cancer.”

  • Specialist support for specialist cancer nurses
    13 August 2018

    Twenty clinical nurse specialists working in cancer across our region recently enrolled on a six month development programme which offers support, development and mentorship.

    The programme, hosted by UCLH, helps to enhance this highly specialist staff group with the skills and qualities they need to work with people with cancer and their families as effectively as they can.

    The clinical nurse specialist (CNS) development programme is offered to all new cancer CNSs in NHS trusts in north and east London and west Essex. This specialist programme comprises some e-learning (provided by Macmillan Cancer Support) and two full study days, one on communication skills, the second on multi-disciplinary team (MDT) working. The latter was led by Professor Alison Leary from London Southbank University. As part of the programme, each CNS is allocated an experienced CNS mentor.

    The programme recently hosted the final study day. UCLH lead cancer nurse Alison Hill said, “We had a very engaging session about the importance of communication – with each other and our wider colleagues, and with patients and their families and carers. Feedback about the programme was really positive and we look forward to welcoming the next cohort in the near future”.

  • Robotic prostate cancer surgery in action
    8 August 2018

    The work of UCLH urological surgeons and their robotic ‘partner’ has been showcased in an in-depth article published in The Observer Magazine.

    Consultant urologist Greg Shaw was featured performing robotic surgery at University College Hospital at Westmoreland Street Hospital to remove a cancerous prostate from a 59-year-old patient. Around 600 prostate operations are performed each year, with the help of the Da Vinci robot technology.

    The operation was part of a clinical trial of a procedure pioneered in German hospitals that aims to preserve microscopic nerves around the prostate – and with them the patient’s sexual function. While the patient is still under anaesthetic, the prostate is couriered to a nearby laboratory to be tested. If no cancer is found at the prostate’s margins, the nerves can be saved and do not need to be removed.

    You can read the full article here.

  • Plans for a new cancer diagnostic hub in north east London – members of a patient advisory group sought
    23 July 2018

    UCLH Cancer Collaborative has secured NHS England funding to develop a new cancer diagnostic service in north east London. The Alliance Diagnostic Hub - the first of its kind - will improve early diagnosis for patients with conditions that increase their risk of cancer, as well as monitoring patients with early stage cancer who do not need treatment right away. We are looking for people who would like to join a new Patient Advisory Group to help shape our plans for the Hub.

    The Alliance Diagnostic Hub is due to open in summer 2019 and will offer various services including MRI scanning, ultrasound and endoscopy. The Hub will be a centre for best practice and training and will spread specialist knowledge across the region.

    People most likely to benefit from this new service include those with gastrointestinal conditions such as polyps, Barrett’s Oesophagus and inflammatory bowel disease; or those with liver cirrhosis or early stage prostate cancer.

    We are looking for patients, carers and family members to become part of a Patient Advisory Group to help us further develop the plans for this new Alliance Diagnostic Hub. No previous experience is necessary, but people will be passionate about early cancer diagnosis, and either have experience of cancer or a pre-cancerous condition, or be a member of the public who is pro-active within their community or a member of a community group in north east London.

    Dr Angela Wong, consultant gastroenterologist and clinical lead for cancer at Barts Health NHS Trust and clinical lead for the diagnostic hub, said:

    “Our plans for a new diagnostic hub in north east London are incredibly exciting and will make a real difference to early diagnosis and patient outcomes. Patient and carer involvement is extremely important to the development of our plans for the hub. This is a great opportunity to co-design a person-centred approach to cancer diagnostic pathways at a dedicated centre.”

    Please visit our get involved in cancer pages for more information about joining the Diagnostic Hub Patient Advisory Group.

    If you would like to find out more about applying to join the Patient Advisory Group, please contact us for an informal discussion. Please email or call 07950 960 159.

  • Be clear on Bladder and Kidney Cancer campaign goes live
    19 July 2018

    UCLH consultant urological surgeon Professor John Kelly is the London spokesperson for the latest ‘Be Clear on Cancer’ campaign focusing on detecting bladder and kidney cancer early.  The ‘Be Clear’ campaigns are run by Public Health England and aim to improve early diagnosis of cancer by raising awareness of symptoms and encourage people to see their GP without delay.

    Every year over 19,000 new cases of bladder and kidney cancer are diagnosed in England causing around 8,000 deaths.  The earlier these cancers are diagnosed, the better the chances of survival are - 84% of those diagnosed with kidney cancer and 77% with bladder cancer at stage 1 will live for at least five years.  At a late stage this drops to 10% and 9% respectively.

    The current campaign focuses on the presence of blood in your pee as a potential sign of something more serious - blood in pee is a symptom in almost two thirds (64%) of all bladder cancers and around a fifth (18%) of kidney cancer.  Only 16% of people most at risk – i.e. age 50 or over – check the colour of their pee every time they go to the toilet.  The campaign encourages people to ‘look before they flush’ and tell their doctor if they notice blood in their pee, even if it’s just once, just to get it checked.

    Prof Kelly said: “Blood in pee always needs further investigation. While in most cases it is nothing to worry about, it could be something serious such as cancer. The earlier (bladder) cancer is caught, the better chance of successful treatment. But we need people to pay attention when they pee and speak to their doctor if they notice blood.”

    The campaign will feature a short film and radio and social media advertising.  There’ll also be advertising placed in key locations like washrooms.  For more information go to

    UCLH is a regional specialist centre for the treatment of urological cancers – to find out more go to

  • Breast cancer education day
    17 July 2018

    The London Cancer breast pathway board held an education day for over 100 clinicians, patients and carers from across north and east London this month.  Chaired by Jasdeep Gahir (Consultant Surgeon, North Middlesex Hospital) and Emma Spurrell (Consultant Oncologist, Whittington/UCLH), the day included updates on current national breast cancer policy and feedback from research studies.

    Speakers included clinicians from across the region, as well as patients and representatives from the third sector. The following topics were covered at the event;

    • Psychological care for breast cancer patients
    • TAILORx trial results - a study which looked at the effects of chemoendocrine therapy versus endocrine therapy alone in low-risk patients
    • Patient experience and access to support services
    • Access to screening, including for people with learning disabilities
    • Neoadjuvant chemotherapy and lymph nodes
    • Patient treatment, genetics and pathology
    • Role of PET CT in breast cancer
    • Treatment related cardiotoxicity
    • Fertility protocols.

    For a more detailed report and for a copy of the presentations visit the breast pathway board pages here and view the board documents.

    Feedback from the day was very positive with lots of suggestions for future topics including stratified follow up and the role of diet and physical activity on cancer.

    Emma Spurrell, consultant oncologist and co-chair, said:

    “I am hugely grateful to the speakers for the high quality of the talks given. There was a good turnout on the day which is so important as it gives us the unique opportunity to meet others who work in our network.”

  • UCLH Cancer Collaborative celebrates another year
    10 July 2018

    Over 150 people gathered at the event in east London which also saw the launch of the Cancer Collaborative’s annual review 2017/18.

    Keynote speakers included Prof Louise Jones from the Barts Cancer Institute and Genomics England speaking about delivering genomic medicine at a population level. We were delighted that speakers and panellists included a number of patients, as well as some of our many partners in the third sector including Cancer Research UK and Macmillan Cancer Support.

    The event programme highlighted some of the key projects undertaken in the Cancer Collaborative in the last year including:


    • Learning from the Cancer Vanguard programme
    • Our work to speed up earlier diagnosis
    • Focusing on best practice cancer patient pathways
    • How we can better measure and track improvement in patient care
    • The benefits of partnership working at scale.

    A selection of speaker presentations are also available to download below. Some presentations are not available due to data sensitivities. If you would like more information about the presentations here, please get in touch by emailing and we will pass your query on.


    Learning from the Vanguard and sustainable impacts – Prof Kathy Pritchard-Jones and Prof Geoff Bellingan

    Session 1: Prevention and earlier diagnosis 

    Teachable moments in north east London – Mary Newell Price

    Plans for the Alliance Diagnostic Hub – Dr Angela Wong

    Session 2: Best practice cancer pathways

    Prostate pathways – Dr Shonit Punwani

    MDT improvement – Holly Norman

    Pathway visualisation work with Public Health England – Donna Chung and Mr John Hines

    Session 3: Measuring and tracking improvement

    Delivering genomic medicine at a population level: beyond the 100,000 genomes project – Prof Louise Jones

    Respect 21 project – Prof Naomi Fulop

    Lung scorecard and ICHOM project - Dr John Conibear and Dr Neal Navani

    Session 4: Benefits of partnership working at scale

    Radiographer role innovation – Dr Nick Wozitzna

    Development of a Pan London Systemic anti-cancer Therapy (SACT) Passport for nurses – Alison Hill

    Accelerate, Coordinate, Evaluate (ACE) Programme – Sara Hiom

    Multi-disciplinary Diagnostic Centres – Dr Andrew Millar

    Working in partnership with Macmillan and delivering the recovery package – Emma Tingley and Avril Van der Loo

  • Recruiting cancer clinical leaders in north and east London to head up boards
    5 July 2018

    UCLH Cancer Collaborative is recruiting four clinical leaders to lead our London Cancer pathway boards and expert reference groups. The London Cancer pathway boards and expert reference groups (ERGs) are made up of patients, primary care representatives and cancer professionals from across north and east London and west Essex.

    The role of these pathway boards and cross-cutting ERGs is to improve cancer care for patients, delivering an integrated care pathway that extends from presentation and diagnosis through to palliative care and living with and beyond cancer. We are recruiting clinical leaders in the following areas:

    • Lung Cancer: Tumour Pathway Director
    • Head and Neck Cancer: Tumour Pathway Director
    • Radiotherapy: Expert Reference Group Chair
    • Cancer Diagnostics (formerly Radiology Expert Reference Group): ERG co-Chair with pathology expertise to work alongside Dr Shonit Punwani, Radiology.

    You can download generic job descriptions for these roles here:

    These roles are significant in terms of both breadth of coverage across the patient journey (from prevention through early diagnosis to treatment and end of life) and geographical influence (across the 11 trusts, 13 CCGs and 3.5 million population).

    The main focus of the tumour pathway director role is to provide tumour pathway specific clinical leadership across the UCLH Cancer Collaborative. The Expert reference group co-chair role provides similar strategic leadership for improvement in cancer specific diagnostics. Eligible clinicians include suitably experienced medical, nursing, AHPs, therapy radiographers and physicists.

    The post holders will be part of a unified clinical leadership team of other Pathway Directors, Expert Reference Group Chairs and other Clinical Leads that drive and support delivery of the objectives for the Alliance and also UCLH in its system leadership role for cancer. The role brings challenge to the traditional model of mostly in-hospital cancer care, making step changes in earlier diagnosis and radically reducing variation.

    Applicants must demonstrate previous experience of leading clinical teams at a high level with measurable impact on patient care and enthusiasm for working collaboratively with other organisations. Applicants must have the support of their Trust’s Medical Director and/or Clinical Lead for Cancer. These roles are not remunerated by the UCLH Cancer Collaborative but we would expect these leadership roles to be reflected in your job plan subject to local agreement. Project management and administrative support will be provided according to the work programme.

    Please send a cover letter outlining your expression of interest in the role CV to by the end of the day on Sunday 22 July.  Informal discussion about the role are welcome with Prof Kathy Pritchard-Jones, Chief Medical Officer.  Please contact Amanda to arrange a time. Provisional interview dates are planned for August 1 and 2.

  • Supporting GPs to highlight the importance of coding and safety netting for cancer
    19 June 2018

    UCLH Cancer Collaborative has developed an e-learning module with Macmillan Cancer Support - Coding and safety netting in the context of cancer to raise awareness amongst GPs of these important tools to improve clinical care and early cancer diagnosis. We are delighted that the module has been accredited by the Royal College of General Practitioners (RCGP)

    The course is suitable for GPs, GP trainees and other primary care clincial staff. The aims of the course are:

    • To be aware of the clinical and non-clinical implications of coding.
    • To raise awareness of the benefits of coding and safety netting in improving clinical care, diagnosis and community management of individuals with cancer and other long term conditions.
    • To gain skills in high quality coding and electronic methods of safety netting within everyday clinical practice.

    Dr Afsana Bhuyia, GP Macmillan Improvement Lead, said: "Coding and safety netting tools are vitally important tools for GPs to actively manage patients that either have a cancer diagnosis or may have cancer. It can improve patient safety, early detection and patient care by enabling GPs to have the most up to date information about their patients available at their fingertips. Our e-learning module guides GPs, trainess and other primary care staff through the process of coding and safety netting so they are fully equipped to use these tools to benefit their patients."

  • One patient’s journey through oesophageal cancer
    12 June 2018

    Mike Ryan, aged 67 from Finchley, was diagnosed with oesophageal cancer in August 2017 after noticing pressure in the back of his throat and regurgitation of thick saliva when he ate. He initially put his symptoms down to indigestion, but a particularly uncomfortable experience while eating in a restaurant with his wife and friends prompted him to see a doctor.

    An endoscopy and biopsy at Chase Farm Hospital concluded that Mr Ryan had cancer in his oesophagus – the tube that connects the throat to the stomach. He was referred to University College Hospital, which is a specialist centre for the treatment of oesophago-gastric cancer. He was initially given chemotherapy to try and shrink the tumour prior to having surgery to remove it.

    The operation was complex and involved opening his chest and abdominal cavity for the removal of the tumour, in addition to repairing his abdominal wall due a large hernia from previous surgery. Mike agreed to have his operation filmed so that clinical staff and patients could learn from his experience. Following surgery, He has received oral chemotherapy and some radiotherapy to continue his treatment.

    Mike has been blind since being born prematurely in the 1950s. He says that this didn’t impact his treatment for cancer but meant that the clinical team tried to explain his treatment in a bit more detail to help with his care.

    There have been ups and downs for Mike – he had some adverse reactions to his initial chemotherapy, which was further complicated by a bleeding ulcer and a skin infection. However, after finishing his full treatment in May he is now doing well and, although still tired, is enjoying being able to eat as normal. Impressively, just three weeks after concluding his final chemotherapy and radiotherapy he felt well enough to share his experiences at the Oesophago-Gastric Cancer Awareness Day held at UCLH on 29 May.

    Mr Ryan commented: “I’d like to thank all the NHS staff involved in my treatment across the region, from Chase Farm to UCH and more. It has been a real team effort and the surgical team at UCH were excellent and explained everything so clearly to me. I really felt in safe hands.”

    Mr Nima Abbassi-Ghadi, surgical registrar in Oesophago-Gastric Surgery, was involved in Michael’s care and organised the Oesophago-Gastric Cancer Awareness Day.

    He said: “We were so privileged that Mike was able to share his experience of oesophageal cancer with other patients, carers and healthcare staff at our awareness day. He gave a unique and genuine insight into his treatment and spoke candidly about some of the ups and downs involved in cancer treatment. I know that his experience will help other patients and NHS staff moving forward.”


  • C the Signs - new cancer support tool piloted in east London
    25 May 2018

    UCLH Cancer Collaborative is supporting the launch of a new cancer decision tool, app and website for GPs and primary care staff in City & Hackney.

    C the Signs has been developed by GPs to help primary care professionals identify patients at risk of cancer, using the latest NICE guidelines. The tool allows GPs to quickly check combinations of signs, symptoms and risk factors, which are cross-referenced across all cancer pathways. The tool enables the GP to identify what type of cancer the patient may have as well as what tests, investigations or referrals a patient may need in under 30 seconds.

    Prof Kathy Pritchard-Jones, Chief Medical Officer at UCLH Cancer Collaborative, said:

    “We are delighted to be supporting the C the Signs pilot in east London as part of our commitment to improving earlier diagnosis and patient outcomes across our region. It should be an incredibly useful tool for GPs and primary care staff in City & Hackney to enable them to identify patients at risk of cancer and allow them to access treatment more quickly.”

    For more information about C the Signs visit

  • Learning from the new cancer therapies training programme
    17 May 2017

    New recruits to UCLH’s cancer therapies team were the first to receive a new two day training programme, with support from the UCLH Cancer Academy.  The programme, which is currently being piloted, aims to provide occupational therapists and physiotherapists with the knowledge and confidence required to deliver consistent, high quality care to patients with cancer.  At UCLH, services covered by the cancer therapies team include adult haematology and oncology, the Teenager Cancer Trust Unit, teenagers and young adults at the Cancer Centre and paediatrics.

    Milly Munn (Physiotherapist –TCT), Charlotte Betteridge (Occupational therapist –TCT) JJ Hudson (Physiotherapist –TYA) & Jess Bell (Physiotherapist – adult haematology) were on the programme and gave the following account of the course:

    “Day one provided in-depth teaching on the pathology of cancer and the management of the disease including surgery, bone marrow transplants, radiotherapy and chemotherapy. The presentations were informative and engaging and provided us with the essential knowledge required to understand the cancer pathway. This helped us understand potential complications patients may face and how this could have a fundamental impact to the personalised therapy treatment plans we deliver.

    “Day two primarily focused on the therapy role within cancer with an emphasis on holistic care empowering patients to live, rather than exist, with cancer. The presentations gave invaluable insight on specific therapy treatment programmes including fatigue management, breathlessness and relaxation which are applicable to working with both children and adults. This gave us the skills and confidence needed to work in this specialist area.

    “We were given the opportunity to have open discussions and ask lots of questions which led to debate and reflection. It was a great experience for everyone regardless of what stage of our career we are currently at, equipping us with theoretical and clinical knowledge. The programme also highlighted areas for self-directed learning. The course content was of very high quality - evidence based with useful resources referenced throughout. The sessions were enjoyed by all of us and the course was a great learning opportunity. Thank you Cancer Academy!”

    Abu Sidhanee, Clinical Lead Physiotherapist for Cancer, led the development of the course with support from the Cancer Academy. He explains how the course has evolved, and some next steps for his team:

    “Developing the course was a great chance for Allied Health Professionals at UCLH to demonstrate they can take the lead and make a difference. This pilot has been a fantastic opportunity for us to take something we were already doing to a much higher level – we have put in a monumental amount of hard work and effort to make the course happen – and it’s been teamwork all the way. The feedback has been overwhelmingly positive and our next steps are to develop the content of our course and to explore how other Allied Health Professionals could benefit from a course like this.

    “None of this could have happened without the backing of the Cancer Academy - we are hugely grateful for their support and guidance. I was delighted to have secured a one-week fellowship with the Cancer Academy and used this time to advance my educational knowledge and teaching skills and to identify what we need to do to develop our course further.”

  • Use your skills and experiences to improve cancer care in London
    30 April 2018

    Are you looking for the opportunity to improve cancer care and speed up diagnosis? At the UCLH Cancer Collaborative, we are looking for people affected by cancer to apply for several important roles! By joining our Patient and Carer Network, you will be the first to hear about new ways to be involved. Read on or click here for more information.

    What are the current opportunities to get involved?

    1. Transform diagnosis of bowel cancer

    If bowel cancer is diagnosed early, there’s over a 90% chance of successful treatment. Currently, people undergo a colonoscopy to detect it, which can be unpleasant. Quantitative faecal immunochemical test (qFIT or FIT) is a new, highly accurate and non-invasive test that detects hidden blood in stool samples. It is also considerably cheaper than a colonoscopy.

    After a successful pilot of FIT, we are setting up a Steering Group to oversee the implementation of this new test in north central London – Barnet, Camden, Enfield, Haringey and Islington. We are looking for up to 3 people affected by bowel cancer to join the Steering Group. This is a great opportunity to be part of a project which could transform diagnosis of bowel cancer.

    1. Drive improvements in patients’ experiences of cancer pathways

    We’re working hard to improve cancer pathways – from diagnosis, treatment, to holistic support and quality of life. We want to speed up diagnosis, increase participation in research, reduce waiting times, and make patient experience of services as good as it can be.

    Our Pathway Boards each focus on a type of cancer tumour, and are responsible for driving these improvements. Pathway Boards meet quarterly, and bring together healthcare professionals and patient representatives. This is an opportunity to have a significant impact on services across the health and care system.

    We’re currently looking for new patient representatives with experience of brain and spine, breast, colorectal (bowel), gynaecology, lung, skin, and hepato-pancreatic-biliary cancers.

    1. Keep the voice of people by affected cancer at the heart of everything we do

    Our Patient Experience and User Involvement Steering Group is made up of people affected by cancer who are passionate about engaging communities and making an impact on the future of cancer care. The Steering Group oversees all of the work we do to improve experience of care and work collaboratively with local communities.

    If you enjoy thinking strategically, are committed to representing the diverse perspectives of everyone affected by cancer and working collaboratively with healthcare professionals, then this could be the opportunity for you.

    We’re particularly keen to hear from people from black and minority ethnic communities, who live in east London boroughs, or who were treated at Barts Health, North Middlesex, Princess Alexandra or Homerton Hospitals.

    Who are we looking for?

    People who have had cancer, or who have been a carer or close family of someone who has, and who would like to get actively involved in shaping the future of cancer services. You don’t need any previous technical knowledge or experience to join our Patient and Carer Network. We are looking for people who:

    • Are passionate about improving services for everyone affected by cancer
    • Enjoy working in a group, sharing ideas and learning from others’ perspectives
    • Can work collaboratively with healthcare professionals and other Network members

    You must have had your cancer treatment at one of the 17 NHS hospitals in our area – please see this map.

    How will we support you?

    • We offer an induction and peer-to-peer events to help you understand our work and how you can contribute effectively
    • We reimburse travel expenses
    • Meetings are held in accessible venues
    • We send quarterly updates on our work
    • Our Patient Experience and User Involvement team offer guidance and support

    How can I find out more?

    Please visit to download application documents for specific roles. You can also email or phone 07950 960 159 to talk to a member of our team about getting involved and ask any questions you have.

    The deadline to apply for these roles is 13 May 2018.

  • UCLH Cancer Collaborative appoints new programme director
    23 April 2018

    Naser Turabi has been appointed as the new cancer programme director for UCLH Cancer Collaborative and will join the team next month.  

    Pinkie Chambers - Lead Pharmacist, Cancer Applied Research

    The cancer programme director will work with the chief medical officer to lead the work of the UCLH Cancer Collaborative, incorporating the Cancer Alliance for north and east London, to improve early diagnosis, outcomes and care for patients in our region.
    Naser brings a wealth of experience from the NHS and the private sector. Most recently Naser has led a large scale operational and workforce transformation at UCLH, and developed a multi-provider partnership for musculoskeletal services in Camden. His NHS roles include head of performance at Whittington Health, and prior to joining the NHS, Naser worked for a strategy consultancy focusing on public sector clients.
    Naser said: “I am looking forward to working with the full breadth of the Cancer Collaborative membership across north and east London and west Essex – from hospital trusts to commissioners, public health leads and patient leaders, to make a real difference to cancer care and patient outcomes. For patients and their carers, early diagnosis, excellent treatment and integrated care are far more important than organisations and structures. Across the region we need to work together to make sure that all those affected by cancer receive a world class service from their NHS.”
    Prof Kathy Pritchard-Jones, chief medical officer for UCLH Cancer Collaborative, said: “I am delighted that Naser has been appointed as programme director for the Cancer Collaborative. His experience working in partnership across NHS organisations and with patients will be extremely valuable in continuing to strengthen collaboration in our region.  As we move forward as the Cancer Alliance for north and east London, the transformation programme that we have developed as part of the Cancer Vanguard remains fundamental to our work. I look forward to working with Naser to continue our work and take it to the next level with new projects and programmes.”

  • Focusing on oral cancer - inter-professional learning event for community healthcare professionals - Pinkie Chambers, Lead Pharmacist, Cancer Applied Research
    18 April 2018

    All cancer patients encounter many health professionals with a variety of symptoms. Sometimes these are symptoms of the cancer itself or side effects of their treatment.

    Community pharmacists, dentists and other community healthcare professionals are ideally placed to help patients recognise the signs and symptoms of cancer and also enable them to better manage sore mouth or other mouth care issues, as a side effect of cancer treatment.  

    Pinkie Chambers - Lead Pharmacist, Cancer Applied Research Over 40 per cent of cancer patients suffer from a sore mouth, also known as mucositis, during treatment and that can impact their quality of life.  People undergoing chemotherapy often present to hospital with this side effect when it has become intolerable and they are unable to eat or drink due to pain and discomfort.  There are many ways to manage this side effect and prevent it worsening.  This can be achieved outside of the hospital setting by dentists or community pharmacists. These professional groups can help patients manage this chemotherapy side effect quickly, and improve people's chemotherapy experience.  

    UCLH Cancer Collaborative and the UCLH Cancer Academy are hosting an inter-professional learning seminar focusing on oral cancer on May 17 2018, 19.00-21.30 at the UCLH Education Centre, NW1. The session will look at the detection, treatment and management of oral cancer with an aim to discuss the patient pathway from detection of disease through to management of oral complications of cancer therapies.

    The session is open to GPs, GP trainees, community pharmacists, dentists and practice nurses. To register for your free place, please click here.

  • UCLH Cancer Colalborative - key achievements, next steps by Kathy Prichard-Jones, Chief Medical Officer
    28 March 2018

    As 31 March approaches – the official end date of the national Cancer Vanguard - it’s important to reflect on the major impact the Vanguard partners have achieved in a relatively short time.  With RM Partners and Greater Manchester Cancer Vanguard Innovation, we serve a collective population of 11 million, within which there are some of the best and worst outcomes for cancer.  It’s been a privilege to lead the work of the UCLH Cancer Collaborative and I am confident we have made significant steps to develop new ways of working which will benefit not only our local population, but for the NHS as a whole.  There is much to be proud of and I would like to highlight some of our key achievements:

    • The many projects in our early diagnosis and prevention programme including supporting the UCL trial to test inviting people at higher risk of lung cancer for a lung health check and low dose lung CT scan, piloting the qFIT test to rule out bowel cancer in high risk symptomatic people, opening five multidisciplinary diagnostic centres (MDCs) to get a faster diagnosis for patients with vague but concerning symptoms and relaunching the ‘small c’ website that is aimed at the needs of our population
    • Development of rigorous standards (known as ‘best practice timed pathways’) for how patients can expect to proceed through diagnostic testing and treatment for lung, oesophageal, colorectal and prostate cancers with our cancer colleagues nationwide
    • Partnering with non-NHS organisations - pharma and industry - to draw upon external expertise to develop innovative ways of working.  For example, working with Amgen delivering some cancer medicines closer to home
    • Sharing and capturing knowledge and data across health economies to help inform service design through the Centre for Cancer Outcomes
    • Securing £7.9 million of non-NHS funding to support our work.

    This sector-wide cancer transformation programme that we have developed as the UCLH Cancer Collaborative over the last two to three years, as part of the national cancer vanguard, forms the bedrock of our continuation as the Cancer Alliance for north and east London.  Our priorities remain improving early diagnosis, working in collaboration with colleagues, developing new ways of working, promoting prevention and raising awareness. We continue to support our cancer clinical leaders to continue their great work across organisational boundaries to create ‘whole system’ pathway improvement and excellent care for all.  Our aim remains simple – to improve patient outcomes whilst reducing variation for all people affected by or at risk of cancer. With this in mind, the patient, their carers and families, remain at the very heart of all we do.

  • Daily Telegraph feature on robotic surgery and bladder cancer
    26 February 2018

    Our surgeons appeared in yesterday's Daily Telegraph in a full page feature about how robotic surgery is being used to treat patients with bladder cancer. 
    Read the article here.
  • An update on the UCLH Cancer Academy by Professor Jonathan Ledermann
    21 February 2018

    The UCLH Cancer Academy launched in 2017 with the support of UCH Cancer Fune, the UCLH Charity and a donation from Amplifi, a local media agency. We are extremely grateful for this support. The Cancer Academy aspires to be a leader in cancer education for staff working in cancer services and for patients, families and carers affected by cancer. I am excited about what we have achieved so far, and our range of planned and developing projects.

    Since our launch, we have been working with staff across our four schools to identify opportunities for them to share their expertise, develop new training courses and improve existing ones. This has included intensive teaching fellowships, helping staff to accelerate the development of education programmes with expert support and teaching skills training to help them to teach with confidence.

    Alongside the development of courses with and for UCLH clinicians, the Cancer Academy will offer a programme of high-quality training for all healthcare professionals.

    This weekend 20 junior doctors will be attending an FRCPath Haematology Part 2 revision course led by Dr Andrew Wilson on behalf of the Cancer Academy. This bespoke training for doctors preparing to sit rigorous professional exams includes the opportunity to practice under realistic exam conditions. Participants will benefit from the support of expert tutors from both UCLH and UCL, and receive practical tips and insight for their assessment. This is a great example of the Cancer Academy’s focus on applied training that meets a tangible need, and makes use of the world leading expertise we have at UCLH. We are delighted with the popularity of this course (it was oversubscribed) and we will offer it on a bi-annual basis.

    As the Cancer Academy grows over the next year, I am looking forward to supporting more clinical staff to become expert educators. We are excited to be focusing on innovative areas, such as projects to develop training to improve the effectiveness of MDT meetings, and an inter-disciplinary cardio-oncology study day.

    Finally, we need your feedback, ideas and suggestions – the Cancer Academy aims to offer dynamic, relevant, engaging education, but we need to know what works, what could work and what could be done better.

    For more information on the Cancer Academy, please visit our website.

    Jonathan Ledermann is the Cancer Academy’s Clinical Lead. He is an honorary consultant in medical oncology at UCLH, professor of medical oncology in the UCL Cancer Institute and Director of Cancer Research UK and UCL Cancer Trials Centre.

  • Targeting rarer cancers – biliary tract cancers
    13 February 2018

    Cholangiocarcinoma and gallbladder cancer are known together as biliary tract cancers and affect the small tubes that connect the liver and the small intestine. They are quite rare cancers in the United Kingdom with less than 2,000 cases diagnosed each year. They are much more common in the Far East largely due to the higher incidence of bile duct infections in these countries. 

    Early diagnosis of biliary tract cancers can be difficult and lengthy requiring multiple investigations. The establishment of specialised hepatobiliary centres throughout the UK has changed this dramatically although, unfortunately, some patients still do not get the opportunity to access this expertise. Because these cancers are often without symptoms until they have advanced and spread, unfortunately few patients are currently suitable for the only possible curative treatment - radical surgery.

    However, there has been a dramatic change in the management of biliary tract cancers recently because research studies have shown that a number of patients have tumours that may be particularly responsive to targeted therapies (also known as molecular targets). Therapies are therefore being developed and trialled in some patients that specifically attack the ‘targets’ in the tumour and may be more effective than conventional treatments such as chemotherapy.

    The case for highly specialised surgical and research based centres is overwhelming and UCLH has led the way in clinical trials with chemotherapy and targeted therapy, and establishing the international standards of care in adjuvant and advanced disease.

    Professor John Bridgewater, consultant in medical oncology, at UCLH said:

    “Many hurdles remain, but biliary tract cancers represent one of the most exciting intensive areas of cancer research. We hope that the current approach of targeted medicine based on the exact type of bile duct cancer that each patient has, will ultimately benefit all and advance the field internationally.”

    For further details please viist AMMF - the cholangiocarcinoma charity

  • Annual Cancer Care conference hosted at UCLH
    24 January 2018

    This Annual Conference was organised by the Cancer Education Programme at UCLH. The programme is funded by Health Education England, and aims to help staff deal more effectively with people with cancer and improve their experience.

    Alison Hill, lead cancer nurse, UCLH, Laura Allington, PBT operational lead, UCLH and Linda Athey, Macmillan lead nurse, North Middlesex University Hospital

    Over 100 delegates attended the day, mainly nurses and therapists from local hospitals, including Barking, Havering and Redbridge University Hospitals, North Middlesex University Hospitals, UCLH and Bartshealth. Speakers included Terri Porrett, Director of the Academy of Fab Stuff and June Davis, National Cancer Rehab Lead, Macmillan Cancer Support. Staff from hospitals across the region also showcased some of their innovative projects.

    Alison Hill UCLH Lead Cancer Nurse said, " This has been an exceptional day with a huge amount of interest in the speakers and discussion both in the sessions and during the breaks. We hope to get funding to run a similar event in 2019.”

  • Key project shortlisted for HSJ partnership award
    11 January 2018

    A key UCLH Cancer Collaborative project has been shortlisted for an HSJ partnership award. These awards recognise and celebrate the best partnerships in health that work for the benefit of both patients and the NHS.

    The ‘out of hospital’ project is designed to bring some cancer treatments closer to home and is a partnership between UCLH Cancer Collaborative and the pharmaceutical company Amgen, as part of the Cancer Vanguard’s Pharma Challenge. Together, we have mapped out how some breast cancer treatments can be delivered in patients' homes or in community settings under the care of their doctor. For patients who want to do this, it can save travel time and waiting in hospital clinics. This is good news for patients and may also demonstrate savings to commissioners.

    The HSJ judges were looking for innovative projects which demonstrate outstanding commitment to working in collaboration with the NHS, cutting-edge innovation and service provision. Additionally, the projects needed to be a beacon of best practice, offer ongoing benefits, add value and not replicate something the NHS could do for itself. The judges were impressed with the high standard of entries, testifying to the clear achievement of any shortlisted organisation.

    The winners of the partnership awards will be announced on Thursday 8 March at the Royal College of Physicians in London.

    More information about our work with Amgen and the Pharma Challenge is available here. You can watch a short film about the project below.

  • Cancer of unknown primary (CUP) education event
    10 January 2018

    UCLH Cancer Collaborative hosted a cancer of unknown primary (CUP) and malignancy of unknown origin (MUO) education event recently for professionals from across London. These relatively rare cancers are diagnosed when cancer cells are found in the body, but the place that the cancer began is not known.

    The all-day event was hosted by Dr Katia Boleti - consultant medical oncologist and London Cancer acute oncology expert reference group chair.

    The first part of the day focused on the multidisciplinary diagnostic centre (MDC) pilot project with a talk from Dr Andrew Millar, consultant gastroenterologist at North Middlesex and project lead and Felicity Carson, project manager. MDCs are for patients with vague, but concerning symptoms, that could be cancer. This was followed by a presentation on MUO primary care referrals by Julia Odzill from the transforming cancer services team for London (TCST). These two talks sparked much discussion amongst the attendees.

    The audience then heard from Dr Nikolaos Diamantis, who spoke of the role of CUP/MUO multidisciplinary teams - how they work, how patients are referred in and the ongoing issues faced.

    The second part of the morning allowed a number of speakers to give their perspective and information on their role diagnosing and treating cancer of unknown primary in patients. Speakers included Dr Martin Harris (GP), Dr John Bridgewater (CUP Lead), Dr David Feuer (Palliative Care perspective) and Emily Keen (CUP CNS).

    After lunch a number of patient case studies were presented by Dr Ishani Patel and Dr Roopinder Gillmore. The day ended with an inspiring talk from Dr Kai-Keen Shiu, clinical lead for the cancer of unknown primary service, and the acute oncology service at UCLH. Dr Shiu spoke about the current opportunities of research and also biobanking.

    Presentations from the event can be found on the London Cancer website.


  • Professor Mick Peake recognised for his work on early lung cancer diagnosis
    29 December 2017

    Professor Mick Peake, clinical director for the UCLH Cancer Collaborative’s Centre for Cancer Outcomes, has been awarded the annual Charles Cully memorial medal by the Irish Cancer Society. Prof Peake was recognised for his work throughout his career on the earlier diagnosis of lung cancer, and improving outcomes for lung cancer patients.

    The annual lecture and award takes its name from one of the most influential founding members of the Irish Cancer Society. This year’s lecture also saw the launch of new research commissioned by the Irish Cancer Society that one in four lung cancer cases are being diagnosed by emergency presentation in Ireland. Out of those cases, the majority of patients’ lung cancer is already at Stage III or IV. Late diagnosis limits treatment options and reduces the chances of survival.

    Accepting the award, Prof Mick Peake said:

    “Efforts to increase the proportion of patients whose cancer is diagnosed at an early stage should be central to any government’s policy programme on cancer care aimed at improving survival rates. We know that the proportion of patients diagnosed by emergency alive one year later is less than a third of those who are referred electively by their GP.

    “It is important not only to collaborate across the UK to improve early cancer diagnosis and survival, but also to work with our colleagues in Ireland to identify new ways of improving cancer outcomes for everyone.”

  • Reflective trees light up UCLH
    20 December 2017

    Reflective Christmas trees are now on display in the UCH Macmillan Cancer Centre, Westmoreland Street, Radiotherapy Unit at UCLH and, for staff, in 250 Euston Road.  These are organised by the UCH Cancer Fund.

    The trees are displayed every year and give patients, supporters, family, friends and staff an opportunity to take the time to reflect on the year gone by and on those we have shared it with. People write a message of thanks, support or remembrance on a reflective heart for a suggested donation of £5 that is then placed on the tree.

    Prof Jeffrey Tobias, chair of the UCH Cancer Fund, said:  “The reflective Christmas trees take pride of place in three UCLH locations where patients with cancer are treated. The messages that patients, family and staff write on the hearts are full of hope and remembrance. The trees and messages provide us all - patients, staff, friends and relatives - with an important to chance to reflect on 2017."

    If you would like to write a message on a reflective heart, please visit the trees in the UCH Macmillan Cancer Centre, Westmorland Street, Radiotherapy Unit and, for staff, in 250 Euston Road and ask at reception. Alternatively you can contact the UCH Cancer Fund directly by emailing or telephoning 020 3447 1885.

  • Transforming the diagnosis of colorectal cancer – largest pilot study of non-invasive test to rule out cancer extended to include more patients
    19 December 2017

    The second phase of a pilot study to see if a simple stool test (known as a qFIT or FIT test) could effectively ‘rule out’ colorectal cancer in patients with abdominal symptoms and reduce the burden on colonoscopy services, has been launched today.

    The qFIT pilot is the largest study of its kind in the UK. The first phase was launched in April 2017 and over 300 patients have been recruited to date through 32 GP practices and 11 hospitals across six NHS trusts in north central and east London and west Essex. The second phase extends the study to a total of 64 organisations (50 GP practices, 14 hospitals) in London and East Lancashire over the next six months.

    Patients that have been urgently referred for a lower abdominal examination, due to suspected cancer, will be asked to take the simple stool test at home as an addition to their assessment. The results of both the qFIT test and the colonoscopy will then be compared to check that the qFIT test has successfully predicted the result of their colonoscopy.

    Previous studies found that the qFIT test could rule out colorectal cancer with over 95% accuracy. The pilot study will look at whether factors such as age, gender or ethnicity may alter the outcome of the qFIT test. In addition, the study is trialling a decision support software tool developed by Medial EarlySign that could identify patients who are at high risk of having colorectal cancer. The software analyses conventional blood test results, age and gender and will be tested alongside with qFIT to see whether it could further improve the efficacy of the qFIT test in ruling out colorectal cancer.

    If the qFIT pilot study is successful and the test is rolled out across the NHS, it could reduce the number of patients experiencing unnecessary colonoscopies by up to 40% and transform the way that colorectal cancer is diagnosed.

    Mr Michael Machesney, pilot lead, chair of the London Cancer Colorectal Pathway Board and consultant colorectal surgeon, said:

    “The vast majority of colorectal cancers are diagnosed at a late stage which is why it is the second biggest cancer killer. We want more people to receive early diagnosis and survive colorectal cancer.

    “If we can successfully prove that the qFIT test can accurately ‘rule-out’ colorectal cancer for patients with lower abdominal symptoms, we can potentially stem the increasing need for colonoscopy resources and transform the way that colorectal cancer is diagnosed. This is good news for hospitals and good news for patients.”

    Mr Ori Geva, co-founder and chief executive officer of Medial EarlySign, said:

    “We believe this research will show the benefits and efficacy of our machine learning solution in support of the qFIT test. We use routine health records and lab test results to flag the level of associated increased risk for colorectal cancer, helping healthcare organizations stratify their population and isolate sub-populations to prioritise their resources for patients who need care most urgently."

    About the qFIT test

    The Quantitative Faecal Immunochemical Test, known as qFIT, detects hidden quantities of blood in a stool sample that could indicate colorectal cancer. It is much more sensitive than other similar stool tests currently being used. There is growing evidence that the qFIT test could accurately ‘rule-out’ colorectal cancer for patients with suspicious lower abdominal symptoms with over 95% accuracy.

    Currently, patients with symptoms such as abdominal pain or blood in their poo are referred by their GP to a hospital for further investigation such as colonoscopy. This involves inserting a small camera through the rectum up into the lower bowel. As well as the qFIT test being highly accurate, it is considerably less expensive than a colonoscopy – approximately £10 per test compared to over £450 for a colonoscopy. It has also shown to be more acceptable to patients than colonoscopy, which can be uncomfortable and carries a small risk of bleeding and perforation.

    The pilot is supported by NICE and NHS England and has also been selected to become part of the NIHR Clinical Research Network (NIHR CRN) portfolio of high quality studies those have the greatest impact and the potential to the deliver the most benefit to patients.

    Participating trusts and GPs include:

    Barking, Havering and Redbridge University Hospitals NHS Trust, Barts Health NHS Trust, East Lancashire Hospitals NHS Trust, Homerton University Hospital NHS Foundation Trust, North Middlesex University Hospital NHS Trust, Princess Alexandra Hospital NHS Trust, Royal Free London NHS Foundation Trust, University College London Hospitals NHS Foundation Trust, Whittington Health NHS Trust.

    Barking & Dagenham CCG: Parkview medical Centre (Dr DP Shah's Practice), St Albans Surgery , Thames View Health Centre (Dr Gs Katlakt's Practice); Barnet CCG: Millway Medical Practice, Holly Park Clinic, Oak Lodge Medical Centre, Penshurst Gardens Surgery, PHGH Doctors , The Speedwell Practice, The Hillview Surgery, The Old Court House Surgery; Camden CCG: Prince of Wales Medical Centre, Swiss Cottage Surgery, West Hampstead Medical Centre; City and Hackney CCG: Elsdale Street Surgery, Springfield GP-Led Health Centre, Well Street Surgery; Enfield CCG: Southbury Surgery, Southgate Surgery, Woodberry Practice; Haringey CCG: Somerset Gardens Family Health Centre, The Muswell Hill Practice; Havering CCG: Central Park Surgery (Kakad), The Greenwood Practice, Maylands Health Care, North Street Medical Care, Petersfield Surgery; Islington CCG: Killick Street Health Centre, Ritchie Street Group Practice, The City Road Medical Centre, The Rise Group Practice, The Tufnell Park Surgery, The Millar Practice; Newham CCG: Dr Pi Abiola's Surgery, Lord Lister Health Centre, Woodgrange Medical Centre;  Redbridge CCG: Ilford Medical Centre, St. Clements Surgery, Wanstead Place Surgery, Glebelands Practice, The Willows Medical Practice, Ilford Lane Surgery; Tower Hamlets CCG: City Wellbeing Practice, St Stephens Health Centre, St Andrews Health Centre, The Chrisp Street Health Centre; West Essex CCG: The Loughton Surgery, Lister Medical Centre, Ongar Health Centre, The Eden Surgeries.

  • Exciting new opportunities for people affected by cancer to shape services
    18 December 2017

    Are you a patient or carer affected by cancer? Would you like to join us to help shape cancer services and improve early diagnosis across our region?

    UCLH Cancer Collaborative is currently recruiting for patients and carers who would like to be involved in a number of exciting opportunities. These include innovative projects for early diagnosis, measuring quality of life after treatment, and looking at driving improvements in patient experience and outcomes for care pathways for specific cancer types.

    You must be committed to working collaboratively and broadly representing the diverse views and needs of people affected by cancer. Participation in other cancer networks and people with links to community groups is considered really helpful.

    Pathway Boards and Expert Reference Groups

    We have several vacancies for people affected by cancer to join our Pathway Boards and Expert Reference Groups. You can find a list of all the vacancies below.

    Each Pathway Board looks at a specific type of cancer tumour (e.g. brain and spine, lung, colorectal and so on). They are responsible for driving improvement across the whole care pathway, from initial symptoms, through diagnosis, treatment, and living with and beyond cancer.

    Each Expert Reference Group focuses on a cross-cutting topic, such as chemotherapy, psychosocial issues, or rehabilitation. They explore opportunities to improve patient outcomes and experience, and offer expert advice to the Pathway Boards.

    If you are interested in applying to be a patient representative, please read the following information and apply by midnight Sunday 28 January.

      Patient Experience and User Involvement Steering Group

      We are seeking applications for people affected by cancer who would like to join our Patient Experience and User Involvement Steering Group.

      This group drives patient experience and user involvement work across the UCLH Cancer Collaborative, ensuring that the views of people affected by cancer are represented at the highest level.

      We want to ensure that the group is representative of the NHS Trusts in the UCLH Cancer Collaborative and the population we cover. Therefore, we would particularly welcome applications from underrepresented Black and Minority Ethnic (BME) communities, and also from people who received cancer treatment from Barts Health NHS Trust, North Middlesex University Hospital NHS Trust, and Princess Alexandra Hospital NHS Trust.

      If you are interested in applying to join, please read the following information and apply by midnight Sunday 28 January

      Quality of Life Pilot Steering Group

      We are piloting a ground-breaking new tool for measuring quality of life for people affected by cancer. Currently, there is no measure to assess how well patients are supported after their cancer treatment. This tool will establish people’s quality of life and their needs, such as help at home or financial advice. We are looking for people affected by cancer who would like to join the Steering Group overseeing and shaping this pilot.

      If you are interested, please read the flyer below and express your interest by 22 January 2018.

      • Quality of life steering group flyer
      • Ways of working
      • Multidisciplinary Diagnostic Centre (MDC) Steering Group

        If a patient has vague, but concerning, symptoms (such as unexpected weight loss or persistent nausea), it can be difficult to ensure they are referred for the most appropriate tests quickly. Often they are sent back and forth between the GP and hospital, until a diagnosis is made.

        To help these patients and to speed up diagnosis, UCLH Cancer Collaborative is currently piloting three Multidisciplinary Diagnostic Centres (MDCs) across the region for patients with vague symptoms that could indicate cancer. We are looking for people affected by cancer who would like to join the Steering Group overseeing this project.

        If you are interested, please read the flyer below and express your interest by 22 January 2018.

        Interested in finding out more?

        If you are interested in any of the opportunities above, or if you would like to join our Patient and Carer Network to receive regular email updates about new opportunities to be involved with the UCLH Cancer Collaborative, please contact us to find out more. You can email  or call 020 344 72779.

  • Working in partnership to bring cancer treatments closer to home
    15 December 2017

    The Cancer Vanguard's Pharma Challenge has seen us work in partnership with the pharmaceutical company Amgen to bring cancer treatments closer to home.  This project has featured in a short film as part of the Royal Society of Medicine's 21st century programme. You can view the film below.

    The film features UCLH Cancer Collaborative director, Nick Kirby, and lead cancer pharmacist Pinkie Chambers, as well as Paola Domizio, a UCLH patient who is taking part in the pilot project.

    UCLH Cancer Collaborative has partnered with Amgen to map out how some breast cancer treatments can be delivered in patients' homes or in community settings under the care of their doctor. For patients who want to do this, it can save travel time and waiting in hospital clinics. This is good news for patients and may also demonstrate savings to commissioners. To read more about it, click here.

  • Gynaecological cancer education day
    13 December 2017

    The London Cancer gynaecological cancer pathway board held an education day at Laird Hall, on the doorstep of the Royal London Hospital. Hosted by Miss Alex Lawrence, consultant gynaecological oncologist at Barts Health NHS Trust and London Cancer pathway board director, clinicians and patient representatives enjoyed a thought-provoking update on the current innovations in gynaecological cancer.

    The afternoon started with a presentation on borderline ovarian tumours by Mr Kostas Doufekas, consultant gynaecological oncologist at UCLH. A new way of reporting ultrasounds using the IOTA simple rules was presented by Dr Anju Sahdev, consultant radiologist at Barts Health. This allows over 80 per cent of adnexal masses to be classified into cancer or not cancer.

    Alex Lawrence gave an informative talk on cancer in pregnancy and presented the cervical cancer audit. Miss Elly Brockbank, consultant gynaecological oncologist at Barts Health, presented on laparoscopic surgery in endometrial cancer and discussed the LACE trial which included information about the new surgical robot at Barts Health.

    The delegates were able to gain the patient perspective via challenging videos of patients with cervical cancer presented by Rebecca Shoosmith from Jo’s Trust. Each talk ended with a Q&A session which allowed delegates to delve deeper into the topics that had been presented.

    Commenting on the day, Alex Lawrence said: “I found this a fascinating afternoon with speakers from across London Cancer. It was a well-attended meeting with over 40 delegates who gave excellent feedback on the event.”

    Copies of the presentations are available here.


  • Focusing on prostate cancer this #Movember
    6 December 2017

    This #Movember (the month when men around the world grow moustaches to highlight and raise money for prostate cancer) UCLH Cancer Collaborative has been sharing good practice and expertise in prostate cancer, specifically earlier diagnosis and  treatment.

    #Movember highlights include:

    • Watch our video with Prof Mark Emberton on transforming the diagnosis of prostate cancer

  • Developing specialist cancer nursing
    29 November 2017

    Twelve clinical nurse specialists (CNSs) working in cancer services across a number of local trusts graduated from the latest development programme this month.

    The programme, funded for the last four years by Health Education England and Macmillan Cancer Support, provides an opportunity for CNSs to develop and enhance their expertise and skills. It is offered to Cancer CNS across the UCLH Collaborative. Through a combination of e-learning and mentorship, over 60 CNSs have graduated from the programme in four years. Areas of learning include effective multi-disciplinary teams, communications and leadership.

    Alison Hill, lead cancer nurse at UCLH said, “This programme is great for cancer nursing. We get great feedback from participants who are keen to take what they’ve learned back into a clinical setting”.

    UCLH is developing the CNS role further by offering mentoring training for the first time. This will enable the development of experienced CNS to support the CNSs on the programme. This was previously provided by other organisations and is “a clear sign of UCLH’s commitment to continuing professional development to cancer nursing”, added Alison.

    For more information about this and other cancer education opportunities for health professionals, researchers and patients, visit our Cancer Academy website pages.

  • Involving people affected by cancer in our work - Patient Experience and User Involvement Steering Group launched
    24 November 2017

    UCLH Cancer Collaborative welcomed 10 members of our new Patient Experience and User Involvement Steering Group to an induction day on 16 November. It was a great opportunity to introduce the members to the wider teams and to the different programmes of work. We explored some of the key patient experience priorities the group members will tackle in their new role. The interactive day brought together healthcare organisations, patients, carers and staff from across the Collaborative and focused on improving early cancer diagnosis, clinical outcomes and patient experience. It concluded with an interactive session led by two current patient representatives from the Haematology pathway board and Living With and Beyond Cancer expert reference group.

    The Steering Group will ensure that views of people affected by cancer are represented at the highest level through the Cancer Vanguard Board (CVB) and Sustainability and Transformation Plan (STP) Cancer Boards. It will drive patient experience and user involvement work across the UCLH Cancer Collaborative and promote a partnership approach whilst maintaining high standards through appropriate levels of discussion and challenge.

    The newly appointed chair of the steering group is Dominic Manley. Dominic is passionately interested in ensuring that the models of cancer care being developed by the Cancer Vanguard meet the holistic needs of all patients. Dominic commented: “As someone with first-hand experience of cancer treatment and a keen interest in the provision of NHS services, my aim is that the Steering Group enables those affected by cancer to become positive and integral contributors to the progress that the UCLH Cancer Collaborative is achieving. I am confident that this approach will lead to an overall improvement in patient care. I am looking forward to working with the new steering group members and Cancer Collaborative team to ensure that patients and carers are fully involved in this important partnership.”

    Nick Kirby, director of UCLH Cancer Collaborative said: “Improving patient experience through dialogue with patients and carers is vital. The launch of this new Group will help ensure that patients contribute effectively and make an impact on the design and delivery of all our work programmes. I look forward to working with the Group in the coming months.”

    Want to find out more?

    If you are a patient or carer interested in getting involved with our work, please email or call 020 3447 2779. A member of our team will get back to you as soon as possible.

  • Cancer division staff event #uclhcancer
    22 November 2017

    Staff working in cancer services were invited to the second UCLH Cancer Division staff event on 22 November. Over 300 staff listened to an agenda which included new and pioneering research, approaches to measuring patient outcomes, improvements in patient experience and to wrap up, some of the 'unsung heroes' of the division - the people that go the extra mile to make our cancer service what it is.

    The poster competition attracted several high quality entries, from teams across UCLH. See photos and comments on twitter - type in #UCLHcancer to see them.

    Many thanks to UCH Cancer Fund for funding this inspirational, educational day.
  • Leading figures chosen for Clinical Advisory Group (CAG) for London
    7 November 2017

    Three leading figures from UCLH Cancer Collaborative have been chosen to sit on the Cancer Commissioning Board Clinical Advisory Group for London. The new body brings together an array of clinical stakeholders to provide clinical oversight in setting the strategic direction for cancer services in London.  The CAG will advise on priorities to ensure London meets and exceeds national cancer outcomes by 2020.

    Sharon Cavanagh, head of the Macmillan Integrated Cancer Programme and Occupational Therapist; Pinkie Chambers, lead cancer pharmacist at UCLH and joint chair of the London Cancer chemotherapy group; and Alison Hill, lead cancer nurse at UCLH and chair of the London Cancer nursing group have all been appointed to the Clinical Advisory Group.

    Sharon Cavanagh said: “We are delighted that UCLH Cancer Collaborative is so well represented on the Cancer Commissioning Board Clinical Advisory Group for London. We are looking forward to using our clinical expertise and knowledge of London’s health system to make a real difference to improving cancer care across the capital.”

  • World class expert training for London doctors in MRI to diagnose and manage prostate cancer
    1 November 2017

    The specialist prostate cancer team at UCLH, with the support of London Cancer and Prostate Cancer UK, is spreading its expertise in using MRI (Magnetic Resonance Imaging) to diagnose and manage prostate cancer.
    The urology and radiology teams at UCL and UCLH, led by Professor Mark Emberton, have been at the forefront of research into multi-parametric prostate MRI, which has been one of the most important advances in prostate cancer diagnosis over the last decade.
    Evidence from a clinical trial has shown that over a quarter of men with suspected prostate cancer could avoid a biopsy if an MRI scan is performed as part of their diagnosis. In addition, the detection of aggressive cancers can be almost doubled by carrying out an MRI followed by a biopsy, as the MRI gives crucial information about where the cancer is and its size.

    The two-day interactive MRI masterclass was developed by the specialist prostate team that includes Veeru Kasivisvanathan, Clare Allen, Caroline Moore and Mark Emberton. Urologists and radiologists, with a special interest in prostate cancer, working across north central and east London, participated in the course to develop the consistent use of high quality MRI across London Cancer to the benefit of patients.

    Clinicians’ performance was measured at the beginning and the end of the course and showed a significant improvement in MRI reporting, with urologists as well as radiologists benefitting from the course.
    Dr Veeru Kasivisvanathan, NIHR doctoral fellow and specialist registrar in urology, said: “This was a fantastic opportunity for us to share our clinical expertise in using MRI to diagnose and manage prostate cancer. The course helped colleagues to understand how MRI imaging can influence treatment as well as how MRI can help guide prostate biopsy.”
    Caroline Moore, reader in urology at UCL, commented: “The unique feature of this course is that it is run and attended by urologists as well as radiologists. This collaborative approach is key to ensuring that men being investigated for prostate cancer have access to the highest quality care. We are delighted that the course has been adopted by the European Association of Urology for training urologists across Europe in understanding the role of MRI in prostate cancer.”

    Prof Kathy Pritchard-Jones, chief medical officer for UCLH Cancer Collaborative, said: “The prostate cancer team at UCLH are leading the field in diagnosis and specialist training. This masterclass is an important step forward in reducing variation across the system, enhancing expertise, increasing capacity and improving patient experience. London Cancer and UCLH Cancer Collaborative are delighted to be supporting this important work to spread expertise amongst doctors in London and, in the future, the rest of the NHS.”
    The prostate MRI masterclass will run again in 2018.

    Throughout Movember – the month when men around the world grow moustaches to highlight and raise money for prostate cancer - UCLH cancer will be sharing good practice and expertise. Keep checking this blog for updates.

  • Shaping the future of cancer nursing
    18 October 2017

    The Lead Cancer Nurse National Forum met for the first time today at UCLH. This meeting, attended by 15 nurse leaders from all over the UK, was supported by the United Kingdom Oncology Nursing Society. The outcome of today's meeting will be to create a national network and vision for leading and shaping cancer nursing for the future. Alison Hill, UCLH lead Cancer nurse (fourth left) and Alison Keen, head of cancer nursing (second left) University Hospital Southampton said, "We were delighted to host this meeting - it's an important step in developing a national voice for cancer nursing".
  • Delivering breast cancer treatment closer to home
    12 October 2017

    UCLH Cancer Collaborative has been running a pilot for breast cancer patients, enabling them to self-administer a drug called denosumab in their own home. Deonsumab is a targeted therapy, delivered by injection under the skin, used for the treatment of secondary breast cancer in the bone.

    Eight patients were enrolled onto the pilot study, which has been running for nine months, and their experience was recorded throughout. Patients were trained by a nurse and given the equipment that they needed before starting injections at home. The majority of patients said that they were happy with self-administering the medicine and found it more convenient.

    One of these patients,  Paola Domizio, has been part of the denosumab self-administration pilot for six months. Paola is undergoing treatment at UCLH for metastatic breast cancer and previously had to come into central London every six weeks for her denosumab injection. At times she had to wait a while in the clinic for the nurse to give the injection. Paola also suffers from some mobility issues as a result of her condition, which can make getting into a hospital a challenge.

    Paola said: “I jumped at the chance of doing my denosumab injections at home as it’s just so much more convenient. I received training from the nursing staff and it’s very quick and simple to inject my­self. It’s easy to remember to do the injection and I know it’s helping me to stay well. I would definitely recommend self-administration to other people that feel comfortable with it.

    The plan is to continue to offer self-administration of denosumab as an option alongside other methods of delivery at UCLH, and across two other trusts in our sector – North Middlesex University Hospital NHS Trust and Royal Free London NHS Foundation Trust.

    Pharmacist Pinkie Chambers, who developed the pilot with Rebecca Roylance, UCLH consultant medical oncologist, said: “Currently some patients can wait for hours in hospital for a simple injection.  Offering self-administration at home, for those that wish to participate, saves patients and carers waiting  time in hospital. In addition, this new model may demonstrate savings to commissioners.”

  • Two UCLH cancer staff in Darzi Class of 2017/18

    Two staff working in UCLH cancer services have been awarded prestigious Darzi Fellowships in the 2017/18 cohort. Specialist Physiotherapist for Haematology Orla McCourt (left) and Cancer Services Pharmacist Nishali Patel (right) will soon begin their year of study after winning places on this sought after programme.

    Darzi fellowships give clinicians the opportunity to take time to build leadership skills outside their normal role. Fellows take on an improvement project and work towards a postgraduate certificate in leadership with a university partner, in this case London Southbank University.

    Orla’s role at UCLH has given her considerable experience of caring for haematology patients with a wide range of needs. “Physiotherapy is really important for these patients – some are in isolation, some are in hospital for long periods of time – maintaining their physical strength and mobility is very important to their overall health and well being”. Orla is taking her specialist expertise to the Academic Health Science Centre King’s Healthcare Partners to help set up a Haematology Institute. This five year programme will offer world class services, innovative training and pioneering research. “I’m really looking forward to getting an understanding of what it takes to get a project of this size and complexity off the ground – things like balancing organisational and service priorities, financial challenges, HR and service redesign. As an allied health professional it will be such a great opportunity to be part of this project, and I hope to return to UCLH with valuable new skills and fresh experiences.”

    Cancer Services Pharmacist Nishali Patel will be a Darzi fellow on a UCLH Cancer Collaborative project working on the delivery of hormonal and other cancer therapies by community pharmacists. The project will aim to seamlessly transition services currently performed in hospitals into community pharmacies. Nishali said, ‘The role of pharmacists is integral to the care of cancer patients at UCLH. This is an exciting opportunity to involve community pharmacists in delivering hormone cancer therapies as a means of integrating cancer services in to primary care. I am looking forward to learning about the financial implications for this project and about strategy implementation for a new care model. I hope to bring back my experiences to UCLH and use my project management skills to continue to drive further changes for improvement in the cancer division.’

    Nick Kirby, divisional manager for cancer said, “Many congratulations to Nishali and Orla. Their success is reflective of the calibre and quality of staff we are so fortunate to have working in cancer services at UCLH. We wish them the very best of luck and look forward to welcoming them, and all they’ve learned, back to UCLH next year”.

  • Calling people with recent cancer experience to join us and make a difference
    13 September 2017

    Are you a patient or carer affected by cancer? Would you like to join us to help shape cancer services and improve early diagnosis across our region?

    UCLH Cancer Collaborative has launched a Patient and Carer Network and a Patient Experience & User Involvement Steering Group for people with recent experience of cancer treatment in north central and east London, and west Essex. See map.

    Joining our Patient and Carer Network means you will hear about a range of opportunities for people with different skills, interests, and a varying amount of time to offer. You must be committed to working collaboratively and broadly representing the diverse views and needs of people affected by cancer. Participation in other cancer networks and people with links to community groups is considered really helpful.

    Opportunities for Network members include:

    • Joining our UCLH Cancer Collaborative Patient Experience & User Involvement Steering Group
    • Joining a Pathway Board or Expert Reference Group
    • Joining a time-bound project group
    • Participating in one-off discussion workshops or focus groups
    • Giving feedback remotely, by email, for example in surveys or on patient information materials, publicity documents
    • Speaking to community groups and raising awareness of cancer as part of our early diagnosis work.

    To join the Patient and Carer Network, or for more information, please email or call 020 344 72787.

    We are also seeking applications for the UCLH Cancer Collaborative Patient Experience & User Involvement Steering Group. We are specifically recruiting a chair, vice-chair and 20 members.

    If you would like to apply for these roles, please review the documents below, and complete the relevant Expression of Interest form by midnight on Wednesday 11 October 2017

    You are eligible to join the Patient and Carer Network and the Patient Experience & User Involvement Steering Group if:

    • You have had treatment for cancer, or have cared for someone who has received treatment for cancer, within the past 5 years. If you are a carer this must be in a personal and unpaid capacity, rather than as a professional.
    • You have received (or the person you care for has received) treatment for cancer at an NHS hospital in the ULCH Cancer Collaborative area. This covers 17 hospitals – please see our map.
    • You are a member of a voluntary and community sector service supporting cancer patients and carers.

    You are not eligible if:

    • You are a current clinical NHS employee or contractor (this includes honorary or unpaid medical or dental posts).

    Download our flyer here.

    If you would like more information about the Patient and Carer Network or the Patient Experience & User Involvement Steering Group, please contact us by emailing or call 020 344 72787 for an informal discussion.

  • Diagnosing colorectal cancer earlier – online education for GPs launched today
    8 September 2017

    UCLH Cancer Collaborative has teamed up with the Royal College of General Practitioners (RCGP) to develop an elearning module about the presentation of colorectal cancer. The 30-minute module, aimed at GPs and other primary care professionals, provides an overview of the colorectal cancer pathway, with a particular focus on the reasons behind late presentation. Diagnostic and screening investigations are also explored, and next steps following referral to the cancer pathway are discussed.

    Colorectal cancer is the fourth most common cancer registered in England and UK's second biggest cancer killer - but if diagnosed early enough there's more than a 90% chance of successful treatment. There has been an increase in the incidence rates of bowel cancer in the UK of 14% since the late 1970s. Cancer survival for colorectal cancer in the UK is much lower than the European average; this is partly explained by later stage diagnosis. Even though the fast track system for suspected colorectal cancer has existed for more than 15 years, there has been no reduction in the proportion of patients presenting acutely. This is baffling, as there has been an almost threefold increase in fast track referrals in the last 10 years.

    This elearning module will be available for the RCGP’s 80,000 registered users, addresses some of the difficult decision making processes that GPs are facing every day when presented with uncertainty around a patient’s lower abdominal symptoms. The module includes NICE’s current guidance on fast track referrals for colorectal cancer, the impact it has on a patient’s life and statistics about the fast track referral system and its likely outcomes.

    We hope that that completion of the module will assist GPs to make appropriate, timely referrals and improve both patient experience and outcomes.

    The Royal College of General Practitioners is the UK’s leading academic body for general practice, with responsibility for setting the standards of GP training, CPD and revalidation. This eLearning module is accessible from here: . Completion of the course counts towards CPD.

  • Helping patients understand urgent cancer referrals
    06 September 2017

    When a GP suspects that a patient may have cancer, they can make a ‘two-week wait’ urgent referral to hospital so that the patient’s symptoms can be investigated fully and quickly.

    There has been a significant increase in the number of urgent referrals under the ‘two-week wait’ criteria in recent years, due in part to increased awareness about cancer signs and symptoms.

    The majority of patients referred urgently to hospital won’t have cancer, but it’s important that they are seen quickly so that cancer can either be ruled out or treatment started quickly when it is more likely to be successful.

    It’s therefore vital that patients understand the importance of the urgent referral, and make sure that they attend their hospital appointment.

    UCLH Cancer Collaborative has been working with trusts and GPs to produce updated guidance for GPs to help their patients understand the significance of a ‘two-week wait’ referral. The new guidance has been published by the Transforming Cancer Services Team as part of the ‘two-week wait’ referral forms for GPs and other primary care referrers (such as dentists and optometrists) in London. The guidance includes:  

    • Making sure that people understand that they are being referred urgently for suspected cancer, whilst reassuring them that most people referred won’t have cancer
    • Making sure that people understand they need to be available for an appointment within two weeks, and often within 7 days
    • Giving patients an information leaflet in the appropriate language
    • Recording additional needs that patients may have that could impact on the appointment
    • Ensuring that contact details are checked and are up to date.

    Dr Afsana Safa is a GP in Westminster and GP lead for the Transforming Cancer Services Team. Afsana said:

    “It’s so important that people who have been urgently referred to hospital, attend their appointment within two weeks so that we can either rule out cancer or begin treatment quickly. We have found that some patients do not fully understand the significance of an urgent referral or even realise that cancer is suspected.

    “We hope that these guidelines will assist GPs in helping their patients understand more about the importance of attending their urgent hospital appointment within two weeks, and in turn help to reduce the number of people not attending.”

    Further information about the guidance can be found here

  • UCLH hosting international leadership conference
    03 August 2017

    UCLH cancer is joining the American Cancer Executives (ACE) to host an international conference in London this year - 12-14 November 2017.
    The event will be aimed at staff - both clinical and non-clinical - who lead, manage and develop cancer services. 
    The agenda features international speakers presenting on a wide range of topics including:
    • Big data for better Cancer Care
    • Access, quality and cost of Cancer Care
    • Working in partnership with private providers
    • Line management/leadership structures for better cancer care
    The challenges we face working in cancer services are similar, regardless of which country we live and work in - the conference aims to share and explore global approaches and best practice to common issues.
    To register, please visit the event website here:
    We look forward to seeing you. If you would like any more information about the conference you can contact our cancer division lead
  • Speeding up diagnosis for patients with vague symptoms
    21 July 2017

    Not all symptoms that patients go to see their GP about are straightforward. For patients with vague, but concerning, symptoms such as abdominal pain, weight loss or painless jaundice, it can be difficult to refer them to the most appropriate tests quickly. As a result, these patients often get sent back and forth between GP and hospital, until a diagnosis can be made.

    To help these patients and to speed up diagnosis, UCLH Cancer Collaborative is currently piloting three multidisciplinary diagnostic centres (MDC) across the region for patients with vague symptoms that could indicate cancer. The three MDCs are currently at Barking, Havering and Redbridge University Hospitals NHS Trust and North Middlesex University Hospital NHS Trust and UCLH (University College Hospital NHS Foundation Trust).

    MDCs are an integral part of achieving both the standards of the new 28-day faster diagnosis plan, as outlined by the Independent Cancer Taskforce and the wider investment in greater diagnostic capacity outlined in the Five Year Forward View ‘Next Steps’ Plan earlier this year.

    Dr Andrew Millar, consultant gastroenterologist at North Middlesex and MDC project lead, said:

    “Diagnosing cancer early saves lives, as the sooner we can start treatment, the better the outlook for the patient.

    “When a patient has vague symptoms, this often initially doesn't indicate a particular type of cancer, so it can be difficult to make sure that they get access to the right tests quickly. We are speeding up earlier diagnosis across our region by piloting multidisciplinary diagnostic centres at three hospitals for patients who have vague, but worrying, symptoms. At these centres, patients can receive the right tests quickly and, if they do have cancer, get access to the right treatment.”

    Watch our video to find out more about MDCs.

    Visit our webpage for more information, including the type of ‘vague’ symptoms that may be appropriate for referral to an MDC.

  • Make patients central to multidisciplinary teams
    13 July 2017

    UCLH Cancer Collaborative has produced an extensive report arguing that patients with cancer should be central to the working of multidisciplinary teams through:

    • Improving the quality of patient information presented
    • Focusing on patient outcomes
    • Freeing up time to discuss more complex cases.

    Watch our video to find out more.

    All patients with a cancer diagnosis are looked after by a specialist multidisciplinary team (MDT) which brings together doctors, nurses and other healthcare staff to ensure high quality diagnosis, treatment and care.

    These teams were first introduced into the NHS 17 years ago and their role, and workload, has grown. In recent years, there have been some concerns that MDTs could work even better for patients and staff.

    UCLH Cancer Collaborative led an in depth study into the effectiveness of multidisciplinary teams across our region. We held workshops and visited 13 multidisciplinary teams, speaking with 12 MDT leads and 36 MDT coordinators.

    The results of our study are detailed in a report, which includes 21 recommendations. Key to this is the need to make patients central to the multidisciplinary team process.

    A key recommendation is to ensure that information on all patients referred to MDTs is complete and high quality. This can be done through use of a proforma that not only captures clinical information about the tumour, treatment and suitability for trials, but also covers more holistic information about the patient’s preferences, other health conditions and their wider needs.

    In addition, MDTs should systematically focus on recording data on patient outcomes through their treatment so that clinical teams can drive up standards of care and improve outcomes for cancer patients.

    Finally, busy MDTs should free up time to discuss more complex cases by prioritising discussion on these patients at the meeting, and monitoring those with cancers that follow very well established treatment plans (also known as protocolised pathways).

    Prof Muntzer Mughal led the review and said:

    “Multidisciplinary teams are at the heart of managing patients with cancer and, when working well, they help make sure that people can access the best treatment and care. We believe that better MDT working will not only release capacity and resources in the NHS, it will also produce better results and care for patients.”

    The UCLH Cancer Collaborative report complements the recommendations made in the recent Cancer Research UK review into multi-disciplinary teams.

    Subject to national cancer transformation funding we will be working, as part of the UCLH Cancer Academy, to support trusts across the region to put the report’s recommendations into practice.

    Download a copy of the report here. For more information, visit our MDT webpage.

  • Teenager and Young Adult Cancer Education Day
    11 July 2017

    Understanding the physical and emotional effects of cancer on teenagers and young adults (TYA) can be a challenge for all of us. UCLH Cancer Collaborative and Royal Marsden Partners came together on 20 June to create an education event for 60 professionals from across London.

    Chaired by Louise Soanes, Teenage Cancer Trust nurse consultant, the informative day covered a variety of topics including clinical trial research, the role of support workers and the best ways to communicate with young people.

    Prof Kathy Pritchard-Jones, chief medical officer for UCLH Cancer Collaborative, opened the event with an overview of where TYA patients fit within the national Cancer Vanguard’s aim to radically improve cancer outcomes and devise new ways of delivering cancer care.

    Louise Soanes, Teenage Cancer Trust nurse consultant, chaired the event

    Louise Soanes - chairing the event

    Highlights of the day included:

    • Dr Rachel Taylor from UCLH Clinical Trials Unit presented BRIGHTLIGHT’s research, aiming to show whether specialist cancer services for teenagers and young adults add value.
    • Dr Rachael Hough updated the event on Acute Lymphoblastic Leukaemia (ALL) demonstrating an increase in survival rates over time.
    • CLIC Sargent helped the delegates understand the nurse educator role and the young people’s community worker role that they are championing in their ‘Care closer to home’ agenda.
    • Lottie Western, TCT lead nurse at The Royal Marsden described the development of the advanced nurse practitioner role, explaining its positive impact on patient experience, multidisciplinary team working, patient outcomes and patient safety.
    • A thought-provoking Q&A session with a parent and young adult who described the impact of cancer on their lives.
    • Dr Julia Chisholm from The Royal Marsden gave an update on soft tissue sarcoma with focus on Rhabdomyosarcomas (RMS) and Synovial sarcoma (SS).
    • PhD student, Gemma Pugh presented her research on health behaviour change in TYA patients, looking at the best times to deliver advice and information.
    • Dr Mike Groszman’s (Consultant Child & Adolescent Psychiatrist) session on ‘communicating with adolescents’ included the issues of teenagers ‘growing up’ whilst simultaneously ‘growing down’ when diagnosed with cancer.

    Dr Rachael Hough, Teenager and Young Adult Cancer Network Coordinating Group chair, said:

    “Around seven teenagers and young adults are diagnosed with cancer every day in the UK. They deserve the best treatment and support possible.

    “I was really pleased to be part of such a thought-provoking and informative day where health professionals, patients and carers came together to really focus on the needs of teenagers and young adults with cancer.”

    To download the presentation slides please visit the London Cancer TYA webpage.

  • UCLH Cancer Collaborative – one year, many successes
    5 July 2017

    Over 130 people joined us at our ‘UCLH Cancer Collaborative – one year on’ conference on Tuesday 27 June. The event brought together patients, clinicians, local government, charities and other stakeholders from across our region (north central and east London, and west Essex) and beyond.

    Keynote speakers included Chris Harrison, national cancer director and Marcel Levi, UCLH chief executive.  We were delighted that the panel discussions included patients and representatives from the third sector, such as CLIC Sargent.

    Chris Harrison - speaking at the event

    The event programme highlighted some of the key projects undertaken in the Cancer Collaborative in the last year including:

    • Our work to speed up earlier diagnosis in lung and colorectal cancers
    • Focusing on the cancer patient pathways to deliver world-class care
    • How we can better measure patient outcomes to improve care and experience
    • Improving communication and care closer to patients’ homes

    The event saw the launch of our UCLH Cancer Collaborative annual review which is available to download here.

    A selection of speaker presentations are also available to download below.  Some presentations are not available due to data sensitivities.  If you would like more information about the presentations here, please get in touch by emailing and we will pass your query on.

    If you came to the conference and didn’t complete an evaluation form, we’re always interested in knowing what you thought of the event and how we can improve – email your comments to

    Presentations are available to download here:


    Keynote speech: Prof Chris Harrison, National Clinical Director for Cancer, NHS England

    Session 1: Prevention and earlier diagnosis - Camden CCG - improving screening uptake. Dr Imogen Staveley, Cancer Clinical Lead, Camden CCG

    Session 1: Prevention and earlier diagnosis - qFIT pilot project. Mr Micahel Machesney, Consultant colorectal surgeon, UCLH, and London Cancer Colorectal Pathway Board Director

    Session 2: World class cancer pathways - MDT improvement project. Prof Munzter Mughal, Consultant upper GI surgeon and London Cancer MDT lead

    Session 2: World class cancer pathways - A year on in haematology - benefits of reconfiguration. Prof Ronjon Chakraverty, London Cancer Haematology Pathway Board Director

    Session 3: Understanding outcomes - ICHOM project. Prof Mick Peake, Clincial Lead for Early Diagnosis, Public Health England, and Director of the Centre for Cancer Outcomes

    Session 4: Improving communications and care closer to home - Breast cancer project - denosumab. Pinkie Chambers, Joint Chair of the London Cancer Chemotherapy Expert Reference Group

    Session 4: Improving communication and care closer to home - Communications and workforce development. Alison Hill, Trust Lead Cancer Nurse, UCLH

    Session 4: Improving communications and care closer to home - Delivering stratified follow-up in primary care for prostate patients. Dr Elizabeth Babatunde, GP and governing body member Enfield CCG

    Session 4: Improving communications and care closer to home - Bringing care closer to home by involving patients and carers to improve patient experience. Dr Tal Heymann, Princess Alexandra Hospital NHS Trust

  • Living with Sarcoma - join us for a webchat on Tuesday 4 July

    To mark Sarcoma UK’s awareness week, we are hosting a ‘Living with Sarcoma’ web chat  next Tuesday 4 July, 1.45pm with lead Clinical Nurse Specialist Anne McTiernan. 

    This web-based conversation allows the public/patients/carers to put their questions to our experts. To join in the conversation please visit this link on Tuesday at 1.45pm or submit advanced questions to  

  • Cervical cancer awareness week – screening saves lives
    20 June 2017

    Last week (12-18 June) was cervical cancer awareness week. UCLH Cancer Collaborative is urging all eligible women in our region (north central and east London and west Essex) to take up their invitation to cervical screening.

    Each year there are 3,200 new cases of cervical cancer in the UK, that’s around nine women diagnosed every day. Around two out of every 100 cancers diagnosed in women are cervical cancer and more than half of cases are women under the age of 45.

    Cervical cancer affects the lower part of the womb, also called the neck of the womb. The main cause of cervical cancer is the human papilloma virus (HPV) – a common virus which in most cases is cleared by your immune system without any problems.

    Cervical screening (also known as a smear test) is open to women aged 25 to 64, and is a very effective way of preventing cancer by finding abnormal cell changes in the neck of the womb (cervix). These changes could lead to cancer if left untreated. They are usually easily treated in clinic which avoids cancer developing.

    Research shows that cervical screening prevents at least 2,000 cervical cancer deaths each year in the UK. Since cervical screening started in the 1980s in Great Britain, rates of cervical cancer have almost halved.

    Yet many women do not attend their smear test (cervical screening). Of the 1.03 million women eligible for screening in our region (north central and east London), only 201,300 took up the opportunity last year – one in five women.

    Dr Alexandra Lawrence, consultant gynaecological oncologist and director of the London Cancer gynaecological pathway board, said:

    “Cervical cancer is very treatable if detected early and it is clear that the cervical screening programme has saved thousands of lives in recent years. Yet many women do not take up the opportunity of this simple screening test for a variety of reasons. These could include being worried about the test itself, not being registered with a GP or not being aware of the importance of cervical screening.

    “Let’s make this cervical cancer awareness week the time when we encourage all eligible women to take up their invitation to cervical screening.

    “It’s also important that women experiencing any abnormal symptoms, such as unusual bleeding or pain, go and see their GP as soon as possible even if you are not due for cervical screening.”

    To have a screening test, women can either book at their GP surgery or at their local sexual health clinic.

    For more information about cervical cancer screening, visit:

    We hosted a webchat with consultant gynaecologist Tim Mould on cervical cancer screening last year - you can replay at any time

  • Local residents invited to free cancer awareness training

    London residents are being invited to receive free training to help them recognise health symptoms that may signify cancer.

    The Highlight Cancer workshop, organised by UCLH Cancer Collaborative with Cancer Research UK, will help people to have simple, yet powerful, conversations with their family, friends and community about cancer and health in general.
    The workshop takes place on Monday 26 June (12.00-15.00) and is FREE to attend. It will help residents to:

    • Understand key messages around cancer awareness
    • Improve confidence and ‘know how’ to make the most of conversations with family and friends, and work colleagues or clients/customers
    • Encourage people to make healthy lifestyle changes, use local services and contact their GP with any concerns.

    Cancer is on the rise and it is thought that one in two people will develop cancer at some point in their lives. At the same time more and more people are surviving cancer – twice as many people survive cancer today than they did 40 years ago. Getting an early diagnosis is crucial to getting the right treatment for cancer.  
    Familiar faces in the community are ideally placed to encourage their friends, family, neighbours and customers to visit their GP if they have any health concerns, or to be able to point them in the direction of local healthy living support services.
    It’s not about being an expert in cancer or health – it’s about having simple, yet powerful conversations that could make all the difference.
    Date: Monday 26 June
    Time: 12.00-15.00
    Location: Redridge CVS, Ilford IG1.
    The sessions are open to all but are particularly targeted at non-healthcare workers. Register to attend here or search Highlight Cancer on
    Prof Kathy Pritchard-Jones, chief medical officer for the UCLH Cancer Collaborative, said:
    “A simple conversation can make all the difference to someone who may be worried about a change to their body. It’s so important that people are encouraged to go to their GP with any symptoms that don’t feel right for them.  Whilst it probably isn’t cancer, if there is a problem, identifying it quickly is crucial to getting an early diagnosis and the right treatment.
    “We are working with Cancer Research UK to train members of the public to have these simple, yet potentially life-saving conversations with their family, friends and local community.”

  • We're award winners!

    UCLH team Amy Smith, Krishna Patel and Sam Morris won the bronze award at the International Clinical Researcher of the year award last week.

    This tough competition tests entrants' competencies and skills in a real life challenge against their peers.  Of the four finalists in the 'clinical site' category, two teams were from UCLH, a huge achievement in itself and a testament to the thriving research expertise at UCLH.

    For more information about the awards go to

  • Talking bowel cancer in Barking

    On Tuesday 30 May, the UCLH Cancer Collaborative will be in Barking with a giant inflatable colon talking to residents about the signs and symptoms of bowel cancer (also known as colorectal cancer). This event is part of the Deflate Cancer project to encourage people to be more aware of cancer symptoms and promote earlier diagnosis.

    Date: Tuesday 30 May
    Time: 10.00-17.00
    Location: Walkway near Asda, Short Blue Place, Barking IG11 8FJ

    >The inflatable colon is a walk through inflatable replica of the human colon that allows visitors to learn about the various stages of bowel cancer, with a guided tour from a healthcare advisor. The event is being organised in partnership with IBO Ltd, Bowel Cancer UK, London Borough of Barking and Dagenham, Barking and Dagenham CCG, and CRUK.

    Bowel cancer is the fourth most common cancer registered in England and the UK's second biggest cancer killer, but if diagnosed early enough there's more than a 90% chance of successful treatment.

    The risk of bowel cancer increases with age and all men and women over the age of 60 are invited to take part in bowel cancer screening every two years. The uptake in Barking and Dagenham for screening is 43%, compared to a national average of 58%. In addition, research has shown that only around 50% of Barking and Dagenham residents understand the key signs and symptoms of bowel cancer (blood in poo, change in bowel habit, unexplained weight loss, extreme tiredness, pain or lump in tummy).

    Join us in Barking on 30 May to find out more.

  • Avoiding delays in investigation and treatment of bowel cancer
    28 April 2017

    As Bowel Cancer Awareness Month comes to an end, the UCLH Cancer Collaborative is focusing on improving two-week wait referrals for suspected bowel cancer. Incomplete and inaccurate referral requests can lead to delays in investigations and treatment. 

    When a GP suspects that a patient may have cancer, they can make a ‘two-week wait’ referral to hospital so that the patient’s symptoms can be investigated fully and quickly. It is very important that the right information is included in the referral form so that there are no delays and that patients are seen by the right team, in the right place at the right time.

    Watch our video on good practice in two-week wait referrals here.




  • Making endoscopy departments more efficient
    27 April 2017

    This Bowel Cancer Awareness Month, the UCLH Cancer Collaborative is highlighting good practice in the diagnosis of bowel cancer (also known as colorectal cancer).

    Endoscopy involves having your body examined from the inside using a small camera on a flexible tube inserted through your mouth or bottom. It is crucial in so many different aspects of patient care – largely in cancer diagnosis and particularly for bowel cancer.

    Endoscopy departments are currently very stretched across the NHS because of the increased demand for these procedures, due to better awareness of symptoms and increased surveillance of high-risk people.

    One way of managing the increase in demand is to try to make endoscopy units work more efficiently. The UCLH Cancer Collaborative is working with the NHS across north central and east London, and west Essex to assess how much additional endoscopy activity could be delivered with existing resources.

    UCLH has devised a new approach that continuously records endoscopy activity in its unit, including reasons for late starts and early finishes. Watch our video to find out more.


  • Watch our Facebook Live chat on bowel cancer
    25 April 2017

    To mark #bowelcancerawareness month, we hosted a Facebook Live chat with consultant gastroenterologist Dr Ed Seward. Ed works at UCLH and is working on the UCLH Cancer Collaborative’s work to diagnose bowel cancer earlier. Facebook Live sessions give the public the opportunity to put their questions to an expert. If you missed the chat, you can replay it any time.

    If you’ve any ideas for future chats, please get in touch, we’re open to ideas – please email

  • Vague symptoms - could it be cancer?
    21 April 2017

    Not all cancer symptoms are clear cut. For patients with so-called ‘vague’ symptoms, such as unexplained weight loss or non-specific abdominal pain, there may be no clear specific underlying cancer types. 

    For these patients it’s often unclear what the right tests are, and which specialists to involve. As a result, patients can get sent back and forth between GP and hospitals, delaying their diagnosis. Sometimes, patients present to emergency departments with symptoms that are later diagnosed as cancer – data shows that 24% of colorectal cancers and one in two pancreatic cancers in north central and east London are diagnosed after attending emergency departments, often with late stage disease.

    In June 2014, NHS England with support from Cancer Research UK and Macmillan Cancer Support started the three year Accelerate, Coordinate, Evaluate (ACE) Programme to drive earlier cancer diagnosis in England. As part of the national ACE programme, London Cancer, now part of the UCLH Cancer Collaborative, initiated pilots of two Multi-disciplinary Diagnostic Centres (MDCs) at University College Hospital and Queen’s Hospital in Romford.

    Our findings, alongside other ‘vague symptoms’ projects in the ACE Programme have now been published - We are very pleased that ACE has made a number of recommendations, including:

    • the need for novel diagnostic pathways for patients that present with non-specific but concerning symptoms, who do not meet current urgent referral criteria guidelines for suspected cancer. This will help to ensure timely diagnosis for these patients.
    • explore options to streamline local diagnostic pathways, including the increased use of clinical nurse specialists as coordinators of patient care and to act as a point of contact for urgent results

    Over the next year, we will continue to work with ACE to explore the concept of MDCs, both in broadening our referral criteria and increasing the number of centres in our locality.

    For more on the ACE programme, go to

  • Straight-to-test can reduce waiting times for bowel cancer testing
    20 April 2017

    The UCLH Cancer Collaborative is supporting the roll-out of the straight-to-test pathway for colorectal cancer (also known as bowel cancer) across our local area.

    Straight-to-test is a telephone-based consultation for patients with symptoms suggestive of bowel cancer.  This can reduce the time that patients wait for a test.

    Under straight-to-test, patients can be seen by their GP, have a phone consultation with a specialist nurse and be given an appointment for an investigative procedure within a few days.

    Helen Pardoe, a consultant colorectal surgeon at the Homerton University Hospital NHS Foundation Trust which runs a straight-to-test service, says:

    “Patients really benefit from having a rapid access to a test which gives them an answer on whether they have colorectal cancer or not. This is a good service for patients and the patients want it. It’s about getting the right patients, to have the right consultation and the right test for their symptoms.”

    Watch and read about how the straight-to-test pathway is working in practice at Homerton University Hospital NHS Foundation Trust.


  • April is Bowel Cancer Awareness month
    2 April 2017

    Bowel cancer (or colorectal cancer) is the fourth most common cancer in the UK with 40,000 new cases diagnosed each year. If detected early, people have an excellent chance of surviving the disease with more than 90 per cent surviving five or more years after an early diagnosis.

    However, the vast majority of colorectal cancers are diagnosed at a late stage which is why it is the second biggest cancer killer. We want more people to receive early diagnosis and survive bowel cancer.

    This April, the UCLH Cancer Collaborative is marking Bowel Cancer Awareness month with a series of activities and case studies to highlight good practice in the early diagnosis of bowel cancer.

    Our first event is this week on Wednesday 5 April. The UCLH Cancer Collaborative will be in Stratford with a giant inflatable colon talking to the public about the signs and symptoms of bowel cancer. This event is part of the Deflate Cancer project to educate the public about cancer and promote earlier diagnosis. Join us opposite the Stratford Centre between 10 and 17.00.

    We will be updating the Cancer blog during April with news and activities, or follow us on Twitter @uclh #bowelcancerawarenessmonth.

  • Welcoming Nick Robinson to our Cancer Centre
    31 March 2017

    We welcomed Nick Robinson of the BBC’s Today programme to the University College Hospital Macmillan Cancer Centre this week. Nick toured the chemotherapy suite with Prof Kathy Pritchard-Jones, chief medical officer for the UCLH Cancer Collaborative. He also spoke to patients and staff working at the centre.

    The piece on improving the diagnosis of cancer was broadcast on the Today programme in the week that NHS England launched its Five Year Forward View refresh document.

    Prof Pritchard-Jones told Nick Robinson about the UCLH Cancer Collaborative’s work piloting specialist centres in London to rapidly diagnose cancer when the patients symptoms are ‘vague’ such as unexplained weight loss or abdominal pain and don’t have a clear tumour pathway. We are delighted that these Rapid Diagnostic Assessment Centres are a key part of NHS England’s Five Year Forward View refresh.

    Listen to an excerpt of the interview. Here is our full response to the NHS England Five Year Forward View refresh.

  • Sharing our learning with Cancer Alliances
    30 March 2017

    The national Cancer Vanguard, which brings together the UCLH Cancer Collaborative, Greater Manchester Cancer Vanguard Innovation and Royal Marsden Partners, held its first national event to share learning with the Cancer Alliances.

    NHS England's National Cancer Director, Cally Palmer, introduced the event by urging the Cancer Alliances to set the pace for change in services.

    A number of UCLH clinicians also spoke to share our work on rapidly improving the earlier diagnosis of cancer, specifically lung and colorectal cancers.

    A write-up of the event, including presentations and posters is available on the Cancer Vanguard website.

    The day in photos
  • Contact Young Company take on cancer - "There is a Light: BRIGHTLIGHT"
    15 March 2017

    UCLH leads on a large scale group of research projects which look at the quality of the provision of services for people aged 13-24 with cancer. The research study, called BRIGHTLIGHT, is developed by young people for young people and aims to make living with the illness more bearable.

    The BRIGHTLIGHT Collaboration involves clinicians and researchers from London, Manchester, Leeds, Birmingham and Southampton. Central to the BRIGHTLIGHT Collaboration is the involvement of young people.

    The BRIGHTLIGHT study has been a direct inspiration for a new production from the award winning Contact Young Company. Directed by award winning artist Adura Onashile There is a Light: BRIGHTLIGHT will premiere at Contact, commissioned as part of SICK! Festival before embarking on two national tours.

    Offering a critical and provocative perspective of how we support young people with cancer in an increasingly stretched Health Service, There is a Light: BRIGHTLIGHT has been created with the help of researchers, clinicians and patients.

    Tickets are priced £13/£7 concession. Over 12’s. Please book online at or call Contact’s Box Office on 0161 274 0600.

  • Cancer Vanguard Early Diagnosis Industry Challenge – launch documents now available

    03 March 2017

    The Cancer Vanguard’s challenge to industry, academics and the third sector to partner with it on projects to improve early diagnosis has now been formally launched.

    The aim of the Early Diagnosis Industry Challenge is to engage expertise from outside the NHS to undertake a small number of high impact projects which will lead to a tangible improvement in the earlier diagnosis of cancer. The call will close on 30 March 2017.

    More information on the Early Diagnosis Industry Challenge, including information about how to submit a proposal can be found on the Cancer Vanguard website.

  • In the news – UCLH Cancer Collaborative

    24 February 2017

    The UCLH Cancer Collaborative has featured on BBC news programmes and BBC online this week.

    Our chief medical officer, Prof Kathy Pritchard-Jones, appeared on the 6pm and 10pm BBC news bulletins talking about centralisation of NHS specialised services. Kathy talked about the benefits of bringing some cancer services together, highlighting our pilot project to try out ways of administering some breast cancer drugs in patients’ own homes to save them coming into hospital.

    Elsewhere on the BBC, an animation to help parents with cancer talk to children about their diagnosis, produced jointly between the Fruit Fly Collective and the UCLH Cancer Collaborative was featured on BBC online. This provoked a tremendous response from the public who shared their moving stories online about their own families’ experiences. The BBC’s shortened version of the film had over 200,000 views on Facebook and their follow-up piece sharing patients’ stories was shared over 530 times.

  • Animation: telling children your child you have cancer

    09 February 2017

    The UCLH Cancer Collaborative has teamed up with the Fruit Fly Collective to create a short animated film to advise parents with cancer on how to talk to their children about their diagnosis.

    It is thought to be the first animated film of its kind and guides parents through discussing their cancer diagnosis with children of different ages, should they wish to.

    By 2020, one in two people born after 1960 in the UK will be diagnosed with some form of cancer during their lifetime. Many of these people will be parents of dependent children – in 2016 there were 7.6 million families with dependent children in the UK.

    Explaining a cancer diagnosis to their child is one of the hardest things a parent can do. But with the right support, children are very good at coping and talking to each other as a family can really help children at this difficult time.  

    The animation uses a cartoon family to give practical tips on telling children you have cancer. Evidence shows that adults respond positively to messages that may be frightening, sensitive or confusing when the information behind the messages is created in a comic-book like format. The animation has also been made into a comic-book for parents, and flyers informing people about the film will be distributed throughout the NHS in the London Cancer area. 

    Dr Mark Barrington, chair of the London Cancer Psychosocial Expert Reference Group and a consultant clinical psychologist, said:

    “It is so important that people diagnosed with cancer receive the right psychological, as well as medical, support. For parents, this can be an especially difficult time and sometimes people are unsure whether or not to tell their children about their diagnosis at all. We were delighted to work with the Fruit Fly Collective to produce the first film of its kind offering clear, practical advice.”

  • Cancer Vanguard launches early diagnosis industry challenge

    03 February 2017

    The national Cancer Vanguard has launched a groundbreaking opportunity for a select group of industry partners to work with them on projects to improve the early diagnosis of cancer.

    The call will launch in late February and close in March 2017.  The aim is to engage expertise from outside the NHS to undertake a small number of high impact projects which will ultimately lead to a tangible improvement in the earlier diagnosis of cancer in the NHS.

    There is a specific focus on two outcomes – first, increasing the proportion of cancers detected at stages 1 and 2. Second, reducing the proportion of cancers detected through accident and emergency.

    We anticipate that successful projects would help improve earlier diagnosis through developing new ways of testing and scanning for cancer; delivering improvements to how patients access services and how patients are referred across clinical teams in different parts of the NHS; and preventing cancer through public health campaigns or working with GPs.

    Projects will be launched in April 2017 and conclude in March 2018.

    The Cancer Vanguard is a unique collaboration between three of the UK’s leading providers of cancer services – UCLH, The Christie and the Royal Marsden. Together, we serve a population of over ten million and have joined together to explore new and innovative ways of delivering services to address the challenges set out by the national cancer taskforce. 

    If you would like more information on the early diagnosis industry challenge, please contact

    Find out more information about our early diagnosis work programme.

  • Highlight Cancer – training for non-healthcare professionals
    31 January 2017

    The UCLH Cancer Collaborative team launched the first Highlight Cancer training session for non-healthcare professionals as part of its earlier diagnosis education and awareness work.

    We have teamed up with Cancer Research UK to roll out these training sessions to increase awareness of cancer signs and symptoms and provide those working in client-facing roles (such as hairdressers, beauticians, café and bar staff) with valuable tips on how to approach conversations about cancer with their customers.

    The first three hour workshop in January was very well attended, and at the end all attendees fed back that they felt they understood the key messages around cancer awareness and the signs and symptoms of a variety of cancers. They also stated that they felt their confidence to discuss cancer had improved and they felt they knew how to make the most of conversations with their customers in the future. Many of the attendees also felt more encouraged to make healthy lifestyle changes, use local services and contact their GP with any concerns. 

    Below is a snapshot of some of the feedback from the session:

    “I learned so, so much and, as the course suggested , I have gone away and I am talking cancer. I am definitely going to pass on the knowledge I have learned.”

    “There were so many amazing facts to hear and dispel and lots of doubts and uncertainties have been put to right. The course content was very well planned and both the trainers were excellent.”

    “Very informative and motivational training session.”

    “I enjoyed the training. The topic is very important and early diagnosis is invaluable. Trainers were good, making a serious topic light-hearted yet taken seriously”.

    “This course should be more widely promoted so that everyone feels more confident to talk about cancer. I will start to use the line 'screening can prevent (some types) of cancer.’”

    Read more about the UCLH Cancer Collaborative’s education and awareness work.

  • Tools to help GPs detect cancer faster
    18 January 2017

    In this video, Macmillan GP improvement lead, Dr Afsana Bhuiya talks about the UCLH Cancer Collaborative's work to help GPs detect cancers earlier and improve the care of individuals living with cancer in the community.

    Working with Macmillan and the Transforming Cancer Services Team for London, we have produced guidance and training for GPs to help them improve their data quality so patients experience better continuity of notes between GP visits. We are also piloting a safety netting toolkit for GPs which is a really practical way to help GPs track patients they are worried about with potential cancer.

    We hope that these tools, and others, can be replicated across the country to help more people diagnosed with and living with cancer.

    Find out more about the Macmillan Integrated Cancer Programme, part of the UCLH Cancer Collaborative.

  • UCLH at the first Global Adolescent and Young Adult (AYA) Cancer Congress in 2016

    At the end of last year (Dec 2016), our teams attended the very first Global Adolescent and Young Adult (AYA) Cancer Congress in Edinburgh hosted by the Teenage Cancer Trust.

    Four hundred delegates from over 19 countries came to the event, the largest ever AYA conference.

    Paediatric Oncology clinical nurse specialist (CNS) Beth McCann was invited to speak at an expert symposium on sex and relationships during cancer treatment and Dr Louise Soanes was also invited to speak on the pros and cons of age appropriate care.

    Of the 18 presentations, four were delivered by UCLH clinicians: Dr Lorna Fern and Dr Rachael Hough, and two of our PhD students, Gemma Pugh and Sarah Lea. UCLH also provided six poster presentations. Many of the Teenagers and Young Adults (TYA) inpatient and ambulatory teams also attended the congress as delegates supporting all those who were presenting.

    During the congress the second edition of the Blueprint of Care was launched which was greatly contributed to by the UCLH nursing team. This document is universally acknowledged as a key document for informing care.

    Rachel Taylor, senior research manager for applied health research on the Cancer Clinical Trials Unit at UCLH said: “I was incredibly proud to attend the congress as a member of the UCLH team representing the trust on an international stage”.

  • Making better use of cancer medicines

    The UCLH Cancer Collaborative is working as part of the national Cancer Vanguard in a novel partnership with the pharmaceutical industry to make better use of medicines.

    As part of the ground-breaking Pharma Challenge, the Cancer Vanguard invited pharmaceutical companies to submit proposals to improve the availability and delivery of cancer drugs.

    The Cancer Vanguard has now signed agreements with two companies, Amgen and Sandoz, to develop their innovative plans, with further agreements expected shortly.

    The Amgen project, which is led by UCLH, aims to map out and measure the most efficient out-of-hospital administration of denosumab, also known as Xgeva ®, a therapy used in patients with advanced breast cancer. This has the potential to bring treatment closer to patients’ homes and help health professionals decide the best treatment ‘pathway’ for individual patients. The project is not intended to promote denosumab over any other similar medicine.

    UCLH pharmacist Pinkie Chambers, who sits on the vanguard’s joint medicines optimisation group, said: “We are excited to be working with Amgen to potentially bring the administration of the breast cancer drug denosumab closer to patients’ homes. If successful, this could be good news for both patients and their carers – saving them time waiting in hospital.”

    Rob Duncombe, Director of Pharmacy at The Christie and chair of the vanguard’s joint medicines optimisation group, said: “Through better use of cancer medicines, the potential to improve patient outcomes and experience, while saving the NHS money, is tremendous.”

    Read more about the NHS Cancer Vanguard working to make better use of cancer medicines.

  • Thomas chops his locks for wig charity

    UCLH Clinical Trial Practitioner, Thomas Taylor, spent his birthday having a very special haircut. Thomas has been growing his hair for 18 months and had his long locks cut off to be made into wigs for children receiving chemotherapy. He also raised money in the process for a genetic disorders charity – PID UK.

    Thomas said: “Kids with cancer need wigs and the Little Princess Trust relies on donations of natural hair to make wigs for children. My hair has got to 12 inches long so will hopefully be of great use.

    “As I’m sacrificing something I’ve come to love, I’m also trying to raise some money to help patients and families affected by primary immune deficiencies.

    “I may need to buy a new hat to get me through the winter months with my significantly shorter new hairstyle!”

    Here at UCLH Thomas helps to research new transplant and gene/cell therapy techniques for cancer patients in his role as a Clinical Trials Practitioner.

  • £6.9m of new funding for national Cancer Vanguard

    NHS England has announced £6.9 million of new funding to support and spread the work of the national Cancer Vanguard.

    The Cancer Vanguard is a partnership between the UCLH Cancer Collaborative, Greater Manchester Cancer Vanguard Innovation and RM Partners (north west and south west London). Together we serve a population of over 10 million and we are working to change the way cancer care is provided. Find out more information on the funding announcement.

  • Reflective Christmas trees light up UCLH
    07 December 2016

    Reflective Christmas trees are now up in the Macmillan Cancer Centre, Westmoreland Street and Radiotherapy Unit at UCLH. These are organised by the UCH Cancer Fund.

    The trees give patients, supporters, family, friends and staff an opportunity to take the time to reflect on the year gone by and on those we have shared it with. People write a message of thanks, support or remembrance on a reflective heart that is placed on the tree.

    Find out more about our Reflective Christmas Trees

  • UCLH Cancer Strategy update Autumn 2016
    06 December 2016

    There’s a lot going on in cancer services at UCLH so here’s our e-bulletin designed to update our stakeholders on the various aspects of the UCLH Cancer Strategy.

    If you would like to receive this update directly, by email, please contact

  • Promoting earlier diagnosis of cancer
    05 December 2016

    The UCLH Cancer Collaborative, which is part of the national Cancer Vanguard, has been promoting the earlier diagnosis of cancer to the public and health professionals.

    The team took a giant inflatable colon to Camden Lock to talk to the public about the signs and symptoms of bowel cancer (also known as colorectal cancer).

    Bowel cancer is the fourth most common cancer in England, and the second biggest cancer killer due to late diagnosis. But if diagnosed early enough there’s more than a 90% chance of successful treatment.

    The inflatable colon is a walk through inflatable replica of the human colon that allows visitors to learn about bowel health including bowel cancer, with a guided tour from a healthcare advisor.

    The Cancer Collaborative also organised an event for public health professionals, CCGs, GPs, academics and voluntary organisations to share learning about successful public health campaigns from across the country that can potentially be replicated in London.

    The audience heard from campaigns across the country including CoppaFeel who encourage women to regularly check their breasts via their network of ‘Boobettes’ – young women diagnosed with breast cancer. And the ‘Small c’ campaign in east London which increased awareness and early diagnosis of cancer through a social marketing campaign amongst target populations.

    Claire Levermore, earlier diagnosis programme lead, said: “Late diagnosis of cancer is one of the key factors that contribute to England’s lower survival rates compared to the rest of Europe.”

    “Our education and awareness programme, part of the national Cancer Vanguard, is taking a multi-pronged approach to targeting and engaging patients, their families, healthcare and non-healthcare professionals in a number of awareness-raising activities over the coming months to help diagnose cancer faster.”

    Find out more information on the UCLH Cancer Collaborative’s education and awareness programme.

  • UCLH Cancer join Gary Lineker to celebrate kids’ radiotherapy fundraising
    21 November 2016

    Prof Jeffrey Tobias, UCLH consultant oncologist, and Kevin Sullivan, Head of Cancer Operations, joined Gary Lineker to celebrate 20 years of the charity Fight for Life. The Fight for Life children’s cancer charity raises money to support the radiotherapy unit treating children at UCLH.

    Photo: Jeffrey Tobias and Kevin Sullivan with Gary Lineker and Fight for Life committee members Yvonne Delane, Cindy Simons and Nikki Benezra.

    Over the last 20 years, Fight for Life has been able to improve the lives of many children and their families at UCLH by raising funds for a whole raft of projects, including:

    • A brand new Linear Accelerator capable of treating with much greater precision and speed than earlier machines.
    • A state of the art PET/CT scanner, giving greater accuracy and allowing us to treat the cancer minimising the harm to growing tissue close by.
    • A TrueBeam accelerator, capable of a higher speed of treatment as well as greater accuracy.
    • The RapidArc project, using computer software to offer versatility for children needing complicated radiation planning and the IGRT (Imageguided radiation therapy ) tools, allowing us to accurately follow and if necessary correct any minor disturbances of the radiotherapy treatment.

    As well as all this world-class radiotherapy kit, Fight for Life maintain the children’s playroom at UCLH which is regularly updated with toys and equipment.

    Prof Tobias, chair of both Fight for Life and the UCH Cancer Fund, said: “The children’s radiotherapy department at UCLH continues to grow and develop with the assistance of Fight for Life.

    “The most exciting development for the future is undoubtedly the delivery of proton beam therapy here at UCLH. As there will only be two proton sites in the UK, children and their families will be travelling from all over the country to receive treatment for up to six weeks. With the help of Fight for Life we would like to make the proton beam playroom the best in the world and more importantly a place where children can escape the rigours of treatment.”

  • Facebook Live web chat: Ask an expert about prostate cancer
    16 November 2016

    For this year’s Movember campaign we held the first ever UCLH Facebook Live web chat broadcast. Our leading expert Professor Mark Emberton came back once more to answer your questions about prostate cancer. Prostate cancer is the UK’s most common cancer in men, killing 10,000 men every year – that’s one man every hour.

    Professor Emberton is at the forefront of research to develop new techniques to diagnose and treat prostate cancer. He is director of surgery at UCL and is an honorary consultant at UCLH. He sees, advises and treats patients at the University College Hospital Macmillan Cancer Centre, as often as possible within a clinical trial setting.

    The conversation focused on the latest research and diagnosing, treating and living with prostate cancer.

    The web chat was broadcast as a live video on the UCLH Facebook Page. You can replay the web chat below.

  • Improving the experience of cancer patients through education
    03 November 2016

    Nick Kirby, Divisional Manager Cancer Services, UCLH

    By Alison Hill, Lead Cancer Nurse, UCLH

    At UCLH we are using funding from Health Education North East London to deliver education to improve the experience of cancer patients. We recognise that neighbouring NHS trusts share similar challenges, so we wanted a forum to share how we are meeting these challenges. Our particular focus was staff working in general areas and the often overlooked role of allied health professionals in cancer care.

    Our first educational event was held on Tuesday – it was great to see 75 health professionals of all disciplines getting together to talk about areas of best practice – for example, how colleagues at Barking, Havering and Redbridge University Hospitals (BHRUT) are using mindfulness for young haematology patients who typically spend a lot of time in hospital. Another example was ‘what good looks like’ in terms of key skills and competencies we should all look for in people caring for cancer.

    The second half of the day focused on developing our resilience. The link between staff and patient experience is well documented and we explored different aspects of how we can care for ourselves as well as we care for our patients. It was great to welcome Barbara Wren to the event – Barbara was instrumental in bringing Schwartz Center Rounds - structured, confidential sessions where we can talk freely about the impact of caring for others – to the UK. We also explored some of the complementary treatments that are on offer to cancer patients, such as art therapy. 

    We were really encouraged to see so many staff and hope that we can continue to develop more educational events to inspire us to offer the best possible cancer care.

    Contact Alison Hill for more details of the event: 

  • Breast Cancer Awareness Month Reception
    28 October 2016

    by Kathy Pritchard-Jones, Chief Medical Officer for the UCLH cancer collaborative and London Cancer

    This week I attended the launch of the All Party Parliamentary Group (APPG) for Breast Cancer's inquiry into geographical inequalities and breast cancer.

    Kathy Pritchard-Jones (left) with Teresa Moss, Director of the Transforming Cancer Services team, London and Dr Will Teh, Chair of the Breast Cancer Pathway Board for Royal Marsden Partners

    It was interesting to hear from the co-chair of the group, Sharon Hodgson MP, about the aim of their review - to understand the extent of variations and make recommendations to reduce inequalities. We also heard from Cally Palmer CBE, national cancer director, about how the ambitions of the National Cancer Strategy align with this review. A patient representative gave us a moving account of her own experience of breast cancer and the importance of access to high quality services.

    Here at the UCLH cancer collaborative, which includes London Cancer, we are working to change the way cancer care is provided, both locally across north central and east London and west Essex, and nationally working with our partners in the NHS. Our breast cancer pathway board is focusing on earlier diagnosis, improving quality and reducing variation, as well as developing new models of care that can bring appropriate care closer to home.

    For more information on the UCLH cancer collaborative and the national Cancer Vanguard click here.

    Professor Kathy Pritchard-Jones is the chief medical officer for the UCLH cancer collaborative and London Cancer.

  • Delivering breast cancer treatment at home
    20 October 2016

    The UCLH Cancer Collaborative (part of the national Cancer Vanguard) has launched a new pilot project for breast cancer patients, enabling them to self-administer a drug called denosumab. It is an injection given just under the skin. Some women with breast cancer need to be treated with denosumab if the cancer has spread to their bones.  Self-administration of injections under the skin is common for many other treatments including DVT or diabetes.

    Pharmacist Pinkie Chambers, who has developed the pilot with Rebecca Roylance, UCLH consultant medical oncologist, said: “Currently some patients can wait for hours in hospital for this simple injection. Our pilot project allows women to self-administer denosumab  if they wish and we appreciate that some may choose not to. The new pilot will, above all else, save patients and carers waiting  time in hospital. In addition, this new model may demonstrate savings to commissioners.”

    Two UCLH patients have been recruited to start the pilot and we hope to recruit around 20 more. If successful, we will propose an alternative commissioning pathway for denosumab for north London that can potentially be replicated across the country.

  • European Oncology Nursing Society (EONS) Congress 2016
    14 October 2016

    We're delighted to report that our expert cancer nurse and Joint Clinical Head of the Macmillan Support and Information Service Hilary Plant will be speaking at the European Oncology Nursing Society (EONS) Congress event in Dublin, Ireland next week (17-18 October 2016). 

    EONS is a pan-European organisation dedicated to the support and development of cancer nurses. The congress will be two days of specialist cancer nursing educational workshops, scientific news, and networking opportunities at the Dublin Aviva stadium.

    Hilary will be speaking on ‘Integrating self-management into clinical care’ and will be tweeting live from the event. You can follow her tweets using Twitter handle @hilaryplant

  • UCLH featured in NHS England Cancer Month
    30 September 2016

    September is Cancer Month for NHS England London and exciting developments at UCLH have been featured as part of this month-long campaign.

    Earlier diagnosis is a key part of our role as part of the Cancer Vanguard. This short film with Professor Sam Janes about earlier diagnosis for lung cancer discusses how earlier diagnosis is helping to save lives.